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SUMMARY 
 
Introduction 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart muscle disease 
characterized by electrical instability leading to ventricular arrhythmias and sudden cardiac death. The 
hallmark pathological lesion of ARVC is the transmural loss of the myocardium of the right ventricular 
(RV) free wall with replacement by fibro-fatty tissue. Three-dimensional electroanatomic voltage 
mapping (EVM) by CARTO system (Biosense-Webster, Diamond Bar, California) allows identification 
and characterization of low-voltage regions, i.e. “electroanatomical scars” (EAS), which in patients with 
ARVC correspond to areas of fibro-fatty replacement. Although the technique has been demonstrated to 
enhance the accuracy for diagnosing ARVC, its value for arrhythmic risk stratification remains to be 
established. Furthermore, the clinical utility of EVM for scar quantification and risk assessment is limited 
by its invasive nature, low availability and high costs. Thus, in daily clinical practice there is the need of a 
non-invasive test such as 12-lead electrocardiogram (ECG) for prediction of the amount of RV 
myocardial scar lesion and assessment of arrhythmic risk. Previous studies demonstrated an association 
between ECG repolarization/depolarization abnormalities and RV mechanical dilation/dysfunction. In 
fact, T wave inversion in right pericardial leads is the most common ECG abnormality of ARVC. 
However, the presence of T wave inversion in leads V1-V3, known as persistence of the juvenile pattern 
of repolarization, may also be observed in about 3% of healthy adults. The current perspective is that, at 
variance with healthy subjects, right precordial NTWs persist with exercise in ARVC patients. However, 
this view is not supported by systematic scientific data. 
 
 
 
4 
 
Objective  
In this work, we aimed to further study some of the electrocardiographic features of ARVC. First, we 
assessed the prognostic value of EAS detected by EVM and its correlation with various non-invasive 
characteristics of ARVC, including abnormalities detected by surface ECG. Second, we studied the 
exercise-induced changes in right precordial negative T waves in patients with ARVC and in a group of 
healthy young individuals with persistence of the juvenile repolarization pattern   
 
Methods and results  
We first studied 69 consecutive ARVC patients (47 males; median age 35 years [28–45]) who 
underwent electrophysiological study and both bipolar and unipolar EVM. The extent of confluent bipolar 
(<1.5 mV) and unipolar (<6.0 mV) low-voltage electrograms was estimated using the CARTO-
incorporated area calculation software. Fifty-three patients (77%) showed ≥1 RV electroanatomic scars 
with an estimated burden of bipolar versus unipolar low voltage areas of 24.8% (7.2–31.5) and 64.8% 
(39.8–95.3), respectively (P=0.009). In the remaining patients with normal bipolar EVM (n=16; 23%), the 
use of unipolar EVM unmasked ≥1 region of low-voltage electrogram affecting 26.2% (11.6–38.2) of RV 
wall. During a median follow-up of 41 (28–56) months, 19 (27.5%) patients experienced arrhythmic 
events. At multivariate analysis, the only independent predictor was the bipolar low-voltage electrogram 
burden (hazard ratio=1.6 per 5%; 95% confidence interval, 1.2–1.9; P<0.001). Patients with normal 
bipolar EVM had an uneventful clinical course. 
Then we further analyzed a subgroup including 49 patients [38 males, median age 35 years] with ARVC 
and an abnormal EVM by CARTO system. At univariate analysis, the presence of epsilon waves, the 
degree of RV dilation, the severity of RV dysfunction and the extent of negative T-waves correlated with 
RV-EAS% area. At multivariate analysis, the extent of negative T-waves remained the only independent 
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predictor of RV-EAS% area (B=4.4, 95%CI 1.3-7.4, p=0.006) and correlated with the arrhythmic event-
rate during follow-up (p=0.03). 
In a different cohort, we assessed the prevalence and relation to the clinical phenotype of exercise-
induced right precordial negative T wave changes in 35 ARVC patients (19 males, mean age 22.2±6.2 
years). Forty-one healthy individuals with right-precordial negative T waves served as controls. At peak 
of exercise, negative T waves persisted in 3 ARVC (9%) patients, completely normalized in 12 (34%) and 
partially reverted in 20 (57%). ARVC patients with or without negative T waves normalization showed a 
similar clinical phenotype. The overall prevalence of right precordial T-waves changes during exercise 
(normalization plus partial reversal) did not differ between ARVC patients and controls (92% versus 
88%, p=1.0), while there was a statistically non significant trend towards a higher prevalence of complete 
normalization in controls (59% versus 34%, p=0.06). 
 
Conclusion 
In conclusion, our results showed that the extent of bipolar RV endocardial low-voltage area was a 
powerful predictor of arrhythmic outcome in ARVC independently of arrhythmic history and RV 
dilatation/dysfunction. A normal bipolar EVM characterized a low-risk subgroup of ARVC patients. 
Patients with abnormal ECG have a more severe RV EAS involvement, which is proportional to the 
extent of T wave inversion across ECG 12-leads and a higher arrhythmic risk. The absence of negative T 
waves characterizes a low-risk subgroup of ARVC patients with a more favorable clinical course because 
of a low rate of arrhythmic events.  
The results also showed that exercise-induced changes of negative T waves were unrelated to ARVC 
phenotypic manifestations and were of limited value for the differential diagnosis between ARVC and 
benign persistence of the juvenile repolarization pattern. 
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RIASSUNTO 
 
Introduzione 
La cardiomiopatia aritmogena del ventricolo destro (CAVD) è una patologia genetica del muscolo 
cardiaco caratterizzata da instabilità elettrica che può portare a aritmie ventricolari e morte improvvisa. 
Dal punto di vista patologico, la CAVD si caratterizza per una progressiva perdita di tessuto miocardico 
della parete libera del ventricolo destro (VD) con sostituzione fibro-adiposa. Il mapaggio 
elettroanatomico tridimensionale (endocardial voltage mapping, EVM) col sistema CARTO (Biosense-
Webster, Diamond Bar, California) consente di identificare e caratterizzare aree di basso-voltaggio, dette 
“cicatrici elettroanatomiche” (CEA), che in pazienti affetti da CAVD corrispondono ad aree di 
sostituzione fibro-adiposa. Nonostante la tecnica abbia dimostrato di migliorare l’accuratezza per la 
diagnosi di CAVD, il suo valore per la stratificazione del rischio aritmico rimane da dimostrate. Inoltre, 
l’utilità dell’EVM per la quantificazione della cicatrice e la valutazione del rischio è limitata dalla natura 
invasiva, bassa disponibilità ed alti costi. Quindi, nella pratica clinica quotidiana è auspicabile la 
disponibilità di un esame non-invasivo, come l’elettrocardiogramma (ECG), per la stima dell’estensione 
della CEA e la stratificazione del rischio aritmico. Studi precedenti hanno dimostrato un’associazione tra 
la presenza di anomalie della ripolarizzazione o della depolarizzazione all’ECG e l’entità della dilatazione 
e della disfunzione del VD. In particolare, l’inversione delle onde T nelle derivazioni precordiali destre 
V1-V3 è uno dei segni distintivi della CAVD. Tuttavia, lo stesso segno ECG può essere riscontrato come 
“persistenza del pattern giovanile di ripolarizzazione” fino al 3% degli adulti sani. La prospettiva attuale è 
che le T negative persistano con l’esercizio nei pazienti con CAVD ma non nei soggetti sani. Tuttavia, 
questa idea non è supportata da dati scientifici. 
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Obbiettivo 
L’obbiettivo dell’attività di ricerca è stato quello di caratterizzare ulteriormente alcune delle 
caratteristiche ECG della CAVD. Inizialmente, abbiamo valutato il valore prognostico della CEA 
all’EVM e la sua correlazione con vari esami non invasivi, in particolare l’ECG. In secondo luogo, 
abbiamo studiato le modificazioni indotte dall’esercizio nella T negative nelle derivazioni precordiali 
destre in un gruppo di pazienti con CAVD ed in un gruppo di soggetti sani con “persistenza del pattern 
giovanile di ripolarizzazione”. 
 
Metodi e risultati 
Sono stati studiati 69 pazienti consecutivi affetti da CAVD (47 maschi, età mediana 35 [28-45] anni) che 
sono stati sottoposti a studio elettrofisiologico endocavitario con mappa di voltaggio unipolare e bipolare. 
L’estensione delle aree contenenti elettrogrammi di basso voltaggio bipolari (<1.5 mV) e/o unipolari 
(<6.0 mV) è stata stimata usando un software incorporato nel sistema CARTO. Cinquantatre pazienti 
(77%) mostravano ≥1 CEA con un’estensione pari a 24.8% (7.2–31.5) dell’estensione del VD alla mappa 
bipolare e del 64.8% (39.8–95.3) alla mappa unipolare (p=0.009). Nei rimanenti 16 pazienti con mappa 
bipolare normale, la mappa unipolare è risultata alterata con un’estensione delle lesioni pari al 26.2% 
(11.6–38.2) del VD. Nel corso di un follow-up medio di 41 (28-56) mesi, 19 (27.5%) pazienti hanno 
avuto un evento aritmico maggiore. All’analisi multivariata, l’unico predittore indipendente di eventi 
aritmici è risultata l’estensione della CEA alla mappa di voltaggio bipolare (hazard ratio=1.6 per 5%; 
intervallo di confidenza 95%: 1.2–1.9; P<0.001). I pazienti con mappa di voltaggio bipolare negativa 
hanno avuto un follow-up privo di eventi. 
Successivamente, abbiamo analizzato un sottogruppo di 49 pazienti (38 maschi, età mediana 35 anni) con 
CAVD e mappa di voltaggio bipolare positiva. All’analisi univariata, la presenza di onde epsilon, il grado 
di dilatazione del VD, la severità della disfunzione del VD e l’estensione delle T negative all’ECG 
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correlavano con l’estensione della CEA alla mappa bipolare. All’analisi multivariata, l’estensione delle 
onde T negative è rimasta l’unico predittore di estensione della CEA (B=4.4, 95%CI 1.3-7.4, p=0.006). 
Questo parametro si è inoltre dimostrato correlare con il rischio di eventi aritmici durante il follow-up 
(p=0.03). 
In una coorte differente, abbiamo valutato il comportamento durante test da sforzo delle T negative nelle 
derivazioni precordiali destre V1-V4 in 35 pazienti con CAVD (19 maschi, età media 22.2±6.2 anni) ed 
in 41 controlli appaiati per età e sesso con benigna “persistenza del pattern giovanile di ripolarizzazione”. 
Al picco dell’esercizio, le onde T negative persistevano in 3 (9%) pazienti con CAVD, normalizzavano 
completamente in 12 (34%) e normalizzavano parzialmente in 20 (57%). I pazienti affetti da CAVD con e 
senza normalizzazione delle onde T durante l’esercizio mostravano un fenotipo simile. La prevalenza di 
normalizzazione (parziale o completa) delle onde T era simile nei pazienti e nei controlli (92% e 88%, 
p=1,0), mentre si è notato un trend non significativo verso una più alta prevalenza di normalizzazione 
completa nei controlli sani rispetto ai pazienti con CAVD (59% e 34%, p=0,06). 
 
Conclusioni 
In conclusione, i nostri risultati hanno mostrato che l’estensione della CEA bipolare alla mappa di 
voltaggio del VD è un potente predittore di rischio aritmico nei pazienti con CAVD, indipendentemente 
dalla storia aritmica e dal grado di disfunzione/dilatazione del VD. Una mappa di voltaggio bipolare 
normale caratterizza una popolazione di pazienti con CAVD a basso rischio. Abbiamo inoltre dimostrato 
che l’estensione della CEA bipolare può essere stimata dall’estensione delle anomalie della 
ripolarizzazione (T negative) all’ECG. I pazienti che non mostrano T negative all’ECG dimostrano un 
basso rischio aritmico. Infine, abbiamo dimostrato che il comportamento delle T negative nelle 
derivazioni precordiali destre V1-V3 non è un utile strumento di diagnosi differenziale tra CAVD e 
benigna “persistenza del pattern giovanile di ripolarizzazione”. 
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INTRODUCTION 
 
 Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart muscle disease 
characterized by electrical instability leading to ventricular arrhythmias and sudden cardiac death(1)(2). 
The hallmark pathological lesion of ARVC is the transmural loss of the myocardium of the right 
ventricular (RV) free wall with replacement by fibro-fatty tissue(3)(4). Three-dimensional 
electroanatomic voltage mapping (EVM) by CARTO system (Biosense-Webster, Diamond Bar, 
California) allows identification and characterization of low-voltage regions, i.e. “electroanatomical 
scars” (EAS)(5)(6)(7)(8), which in patients with ARVC correspond to areas of myocardial depletion and 
correlate with the histopathological finding of myocardial atrophy and fibro-fatty replacement at 
endomyocardial biopsy(9). EVM was proven to improve the accuracy for diagnosing ARVC in 
comparison to other diagnostic tests(8)(9). Although the technique has been demonstrated to enhance the 
accuracy for diagnosing ARVC, its value for arrhythmic risk stratification remains to be established. 
Furthermore, the clinical utility of EVM for scar quantification and risk assessment is limited by its 
invasive nature, low availability and high costs. Thus, in daily clinical practice there is the need of a non-
invasive test for prediction of the amount of RV myocardial scar lesion and assessment of arrhythmic 
risk. 
The electrocardiogram (ECG) is one of the oldest and most versatile non-invasive cardiac tests. It has 
remained in use essentially in its original form despite dramatic advances in cardiac electrophysiology. In 
May 1887, Augustus Desire´ Waller recorded the first human Electrogram using a primitive instrument 
called a Libbmann capillary electrometer. It had 2 deflections corresponding to ventricular depolarization 
and repolarization(10). In 1903, Willem Einthoven invented the String Galvanometer—a more 
sophisticated voltage recording instrument and recorded an Elektrokardiogramm with 5 deflections that 
he named PQRST(11). Surface 12-lead ECG has traditionally been an integral part of non-invasive 
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evaluation of ARVC patients. The ECG has an established clinical value for diagnosis of electrical 
abnormalities of ARVC, consisting of depolarization/repolarization changes and ventricular 
arrhythmias(12). Demonstration of late potentials on signal averaged ECG (SAECG) provides additional 
information on intraventricular conduction defect(13)(14)(15). Previous studies demonstrated an 
association between ECG repolarization/depolarization abnormalities and RV mechanical 
dilation/dysfunction in ARVC patients(14)(15)(16). It remains to be elucidated whether those ECG 
abnormalities correlate with the electrical consequences of fibro-fatty myocardial replacement, evidenced 
as EAS.  
T wave inversion in right pericardial leads is the most common ECG abnormality of ARVC, present in up 
to 80% of ARVC patients(13)(14). However, the presence of T wave inversion in leads V1 to V2/V3, 
known as persistence of the juvenile pattern of repolarization, may also be observed in about 3% of 
healthy adults(17)(18)(19)(20)(21). The current perspective is that, at variance with healthy subjects, right 
precordial NTWs persist with exercise in ARVC patients. However, this view is not supported by 
systematic scientific data.  
In this work, we aimed to further study some of the electrocardiographic features of ARVC. First, we 
assessed the prognostic value of electroanatomical scar (EAS) detected by endocardial voltage mapping 
and its correlation with various non-invasive characteristics of ARVC, including abnormalities detected 
by surface ECG. Second, we systematically studied the exercise-induced changes in right precordial 
negative T waves in patients with ARVC.   
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Historical background 
 Giovanni Maria Lancisi (1654-1720) was an anatomist, clinician, epidemiologist, advisor to Pope 
Clement XI and one of the greatest Italian physicians of the first half of the 18
th
 century (Figure 1). In his 
book, De Motu Cordis et Aneurysmatibus, Lancisi reported a four generation family with sudden deaths 
and dilatation and aneurysms of the right ventricle(22). Two hundred and thirty years later, the University 
of Padua set the first milestone for the modern description of ARVC, as in 1961 and 1965 Sergio Della 
Volta first reported cases with “auricularization of the RV pressure” in which he described a series of 
patients with RV chamber with no effective systolic contraction, with the blood being pushed to the 
pulmonary artery mainly due to the right atrial systole(23)(24). Although the patients presented also with 
ventricular arrhythmias, Della Volta focused more on the hemodynamic features of the cases. One of the 
original patients reported by Della Volta underwent cardiac transplantation 30 years later in 1995 at the 
age of 65 because of congestive RV failure. The left ventricle was normal, whereas the RV was hugely 
dilated with diffuse paper-thin free wall and complete disappearance of the myocardium (figure 2) (25). 
In 1982, Dr. Frank Marcus (University of Arizona, United States) collaborating with a French group of 
researchers described the disease of right ventricular dysplasia in a series of 24 patients referred to La 
Salpetrière Hospital and Jean Restand Hospital in Paris from 1973 to 1980. The group characterized some 
of the fundamental clinical elements of the disease including the T wave inversion in the right precordial 
leads on the surface electrocardiogram (ECG), the left bundle branch block pattern of the QRS complex 
during spontaneous ventricular tachycardia, and the echocardiographic features of normal left ventricle 
with enlarged and aneurismal right ventricle(26). In 1986, Protonotarios et al, studied nine cases of 
palmoplantar keratosis in the Greek island of Naxos, of which seven showed symptoms and signs of heart 
disease. Three cases had episodes of ventricular tachycardia (VT) and a fourth patient died suddenly.  
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Figure 1. Giovanni Maria Lancisi (1654-1720), 
was an Italian physician, epidemiologist and 
anatomist. He observed marked neck venous 
pulsations with tricuspid valve insufficiency 
(later to be known as Lancisi’s sign) and 
associated aortic arch aneurysms with syphilis 
in his masterpiece in cardiac pathology; De 
Motu Cordis et Aneurysmatibus (On the motion 
of the heart and on aneurysms) which was 
published posthumously in 1738. In this book 
also he reported the first known family of 
sudden cardiac death and right ventricular 
aneurysms. 
 
Figure 2. Professor Sergio Dalla 
Volta, the title of his original 
article, and the cardiac specimen 
at transplantation of one of his 
patients. Source: Thiene G. 
“Arrhythmogenic  
ardiomyopathy: from autopsy to 
genes and transgenic mice (SCVP 
Achievement Award Lecture, San 
Antonio, TX)
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All patients with cardiac signs and symptoms showed echocardiographic enlargement of the right 
ventricle and a right ventricular band. Moreover, the left ventricle was also affected in 3 patients(27). The 
described cardiocutaneous syndrome, coined as “Naxos disease”, is an autosomal recessive form of 
ARVC (figure 3). The current concept of the clinical and pathological picture of ARVC was again 
established in the University of Padua. Familial occurrence of ARVC with autosomal dominant pattern 
and incomplete penetrance was proven by Nava, et al. in 1988(28). Furthermore, Thiene et al. associated 
the pathology of ARVC with a series of SCD in the (≤35 years), mostly during effort. All the cases had T 
wave inversion on the right precordial surface ECG at rest and left bundle branch block QRS pattern 
during the ventricular tachycardia(1). This was the first time ARVC was acknowledged as a major cause 
of death in the young.  
 
Incidence 
 ARVC incidence is estimated to be 1 in 2,500 to 5,000 in the general population with male 
predominance(2). It is considered one of the major causes of sudden cardiac death (SCD) in the young 
and young athletes(1). Athletes affected with ARVC represent a specially high risk of SCD group(29). 
ARVC had been traditionally associated with the Mediterranean region, as many seminal studies had 
originated from research groups in France, Greece, and Italy. Today, however, numerous ARVC registries 
from all over the world emphasize that the disease does not have a specific racial or geographical 
predilection (figure 4) (30).  
 
Pathology 
 The pathological diagnosis of ARVC has been traditionally based on the gross and histological 
evidence of transmural myocardial loss with fibrofatty replacement of the right ventricle (RV) free wall, 
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extending from the epicardium toward the endocardium(1). Gross morphological findings of ARVC 
include focal areas of severe muscle thinning –that may transillimunate under a light source-, local or 
global ventricular cavity enlargement, and ventricular wall aneurysms. Aneurysms are only present in 20 
to 50% of autopsy cases of ARVC(31)(4). RV aneurysms, located in the triangle of dysplasia (inflow, 
apex, outflow tract) are considered pathognomonic for ARVC(26). However, autoptic features of ARVC 
may range from grossly normal hearts, in which only a careful histopathological investigation can reveal 
ARVC features, up to massive RV and/or LV involvement.  
 
 
Figure 3. Clockwise from left: The Greek island of Naxos. A nuclear Naxos disease family. Analysis 
reveals the presence of mutant allele (one bold band) in the homozygous boy and the wild-type (two light 
bands) coexisting with the mutant one in the heterozygous carrier parents. Keratoderma striate in palmar 
and diffuse in plantar areas in the homozygous boy. Wooly hair. 
Source: Protonotarios N and Tsatsopoulou A, ‘Naxos Disease and Carvajal Syndrome: Cardiocutaneous 
Disorders That Highlight the Pathogenesis and Broaden the Spectrum of Arrhythmogenic Right 
Ventricular Cardiomyopathy.’, Cardiovascular pathology, 13 (2004), 185–94. 
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Figure 4. The global perspective of ARVC: ARVC has been reported and studied in Europe, Middle East, 
South Africa, India, China, Japan, Australia, North America and South America. 
Source: Elmaghawry M, et al., ‘A Global Perspective of Arrhythmogenic Right Ventricular 
Cardiomyopathy.’, Global cardiology science & practice, 2012 (2012), 81–92. 
 
Therefore, the existence of cases with biventricular involvement or predominantly with LV or RV 
involvement suggest the use of the more comprehensive term arrhythmogenic cardiomyopathy (AC) 
instead of the limiting ARVC (32) (33). 
Histological examination reveals islands of surviving myocytes interspersed within fibrous and fatty 
tissue. Clusters of dying myocytes provide evidence of the acquired nature of myocardial atrophy, and are 
frequently associated with inflammatory infiltrates (figure 5) (32). Rather than being a continuous 
process, disease progression may occur during periodic bursts. Environmental factors, such as exercise or 
inflammation, may facilitate onset and progression of myocyte loss and fibrofatty replacement(34). The 
deposition of adipose tissue is a peculiarity of ARVC, however its specificity has been controversial. 
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Significant fat infiltration of the RV is reported in more than 50% of normal hearts in the elderly(35). It 
has been recently suggested that isolated adipose replacement of the RV myocardium should only be 
considered pathological if observed in association with myocytes at various stages of cell death(36).  
 
 
Figure 5. Arrhythmic cardiomyopathy pathology. A: Cross section of a heart of a 17 year old male who 
died suddenly during a football match. Note the right ventricular dilatation, fibro-fatty replacement and 
anterior and posterior wall aneurysms. B: Histology of the right ventricular free wall of the same patient 
showing transmural fibrofatty replacement. C: Histology of the left ventricular free wall showing focal 
subepicardial left ventricular involvement. 
Source: Thiene G, Corrado D, Basso C, ‘Arrhythmogenic Right Ventricular Cardiomyopathy/dysplasia.’, 
Orphanet journal of rare diseases, 2 (2007), 45. 
 
Pathogenesis  
 Many theories have been postulated to explain the mechanism of the loss of the ventricular 
myocardium and its substitution by fibrous and fatty tissue: dysplasia, myocarditis, transdifferentiation, 
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and dystrophy. The original concept of the disease as congenital abnormality (dysplasia, aplasia, or 
hypoplasia) characterized with maldevelopment of RV myocardium(26). This led to the historical 
confusion in literature between ARVC and Uhl's anomaly. Henry Uhl, at the Johns Hopkins Hospital in 
Baltimore, in 1952, reported a case of an almost total absence of the myocardium of the RV in a 7-month-
old infant, with the epicardium and endocardium lie adjacent to each other with no intervening cardiac 
muscle and no fibrofatty tissue observed in the RV free wall(37). On the contrary in ARVC, myocardial 
death occurs after birth, usually during childhood, and is progressive with time. Another theory was the 
inflammatory process; with myocardial loss due to infective or immune mechanisms. Cardiotropic 
viruses, such as adenovirus, hepatits C virus, and parvovirus B19, have been reported in the myocardium 
of some AC patients(38). However, the viral agent might be just an innocent bystander or play a 
secondary role to the progression of myocardial loss. Transdifferentiation of myocytes into fibrocytes 
and/or adipocytes has also been proposed(39). This theory is questionable because of the limited de-
differentiaton capabilities of adult cardiomyocytes. Myocyte dystrophy remains the most likely 
explanation to the ARVC pathological process. Similar to skeletal muscle dystrophy observed in 
Duchenne or Becker diseases, a progressive and acquired myocardial atrophy with replacement by 
exuberant fatty and fibrous tissue occurs in the hearts of ARVC patients. This dystrophy, either by 
apoptosis or necrosis, could account for a genetically determined loss of 
myocardium(4)(34)(40).Transgenic animal models have been recently developed, supporting the 
dystrophy theory. A transgenic mouse with cardiac-restricted overexpression of the C-terminal mutant 
(R2834H) desmoplakin has been shown to develop increased cardiomyocte apoptosis, myocardial 
fibrosis, and lipid accumulation as well as biventricular dilatation/dysfunction(41). In another seminal 
study of a transgenic mouse model (Tg-NS) with cardiac overexpression of desmoglein-2 gene mutation 
N271S, clinical features of AC, as well as, myocyte necrosis were obsereved in all Tg-NS hearts(42). 
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Role of Desmosomes in Arrhythmic Cardiomyopathy Pathogenesis 
 Desmosomes are a specific type of cell junction within intercalated discs, the specialized 
intercellular junctions of cardiomyocytes (Figure 6). They form membrane anchorage sites for 
intermediate filaments, and the resulting complex is thought to impart tensile strength and resilience. The 
cardiac desmosomes have been proposed to support structural stability through cell-cell adhesion, to 
regulate adipogenesis and apoptosis related genes, and to maintain proper electrical conductivity through 
the regulation of gap junctions and Ca
2+
 homeostasis. Functionally, desmin forms intermediate filaments 
in mature striated muscle that surround the Z discs and link the entire contractile apparatus to the 
sarcolemmal cytoskeleton, cytoplasmic organelles and nucleus. Desmoplakin (DSP) and junctional 
plakoglobin (JUP) are constituents of the submembranous plaques of the desmosomes, along with 
plakophillin (PKP), and they form part of the link between the intermediate filament cytoskeleton and the 
cytoplasmic tail of cadherins. The desmosomal cadherins are calcium-dependent cell adhesion 
glycoproteins, divided in two classes namely, the desmoglein (DSG) and the desmocollin (DSC), and they 
mediate lateral and transcellular desmosomal adhesion (Figure 6&7).  
A desmosomal protein alteration may compromise either cell to cell adhesion and/or intermediate 
filament (desmin) function. The right ventricle with its thinner wall and higher distensibility is 
particularly vulnerable to the impaired cell adhesion. In contrast, disruption of intermediate filament 
(desmin) binding, such as in desmoplakin mutation since it is directly interacting with desmin, may result 
in dominant and/or severe left ventricular involvement. In either case, this mechanical disintegration will 
eventually lead to significant ventricular myocyte loss, especially during higher volume state loads, as for 
example, during sports activity. Because the regenerative capacity of the myocardium is limited, repair by 
fibrous or fibrofatty replacement takes place. This fibrofatty islands are the substrate for macro-reentry 
ventricular arrhythmias. Re-entrant tachyarrhythmias circle around the fibrous tissue and into an isthmus 
of surviving myocytes, in a figure of 8 fashion similar to that occurring around ischemic myocardial scars. 
Moreover, disruption of desmosomal integrity per se can alter the electric stability of the myocytes, 
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regardless of the extent of myocyte loss. For example, it has been recently demonstrated that PKP2 
associates with sodium voltage gated channels Na(V)1.5, and that knockdown of PKP2 expression alters 
the properties of the sodium current, and the velocity of action potential propagation in cultured 
cardiomyocytes(43). 
 
Heritability 
 ARVC cases have been shown to have a genetic component, with approximately one-third to one-
half of them being familial. The inheritance pattern is autosomal dominant, i.e. both mutation 
homozygotes as well as heterozygotes can develop ARVC, although rare autosomal recessive cases – 
where only mutation homozygotes can present with the disease – have also been reported(44). ARVC 
causing mutations have variable expressivity, with highly variable phenotypes, ranging from severe 
disease with early death to individuals who were completely asymptomatic late in life, even among family 
members carrying the same gene mutation(45)(46).  
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Figure 6. The desmosome consists of three families of proteins: the desmosomal cadherins, desmocollin 
and desmoglein, members of the armadillo family of proteins, plakoglobin and plakophillin and the 
plakins. Binding of these proteins tethers desmin intermediate filaments to the plasma membrane in 
cardiac myocytes and adheres adjacent myocytes together. 
Source: Elmaghawry M, et al., ‘Science and Practice of Arrhythmogenic Cardiomyopathy: A Paradigm 
Shift.’, Global cardiology science & practice, 2013 (2013), 63–79. 
 
Penetrance is incomplete (20-30% or higher), with a significant percentage of the mutation carriers not 
presenting with an unaffected, normal phenotype(47). Interestingly, gender may have an influence on 
penetrance, with male mutation carriers more likely to develop specific phenotypic manifestations of this 
disease(31). The reduced penetrance along with variable expressivity, suggest that other genetic modifiers 
and/or environmental factors are implicated in disease pathogenesis. At the genetic counseling level, these 
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characteristics make it difficult to trace the disease along a family line and to identify the members at risk 
of carrying a mutation.  
 
 
Figure 7. Electron microscopic view of cardiac myocyte intercalated discs. (A) Normal case control. 
Regular cell membrane (arrows) and intercalated disc between adjacent myocytes. (B) ARVC patient with 
desmoplakin gene splice site mutation . Note the abnormal position of long desmosomes (arrowhead) and 
the widened gap of facia adherens (arrow). Original magnification: X15 000. 
Source: Basso C, et al., ‘Ultrastructural Evidence of Intercalated Disc Remodelling in Arrhythmogenic 
Right Ventricular Cardiomyopathy: An Electron Microscopy Investigation on Endomyocardial Biopsies.’, 
European heart journal, 27 (2006), 1847–54. 
 
Genetics 
 AC causative mutations have been identified in ten different genes, although two of these 
(TGFB3 and RYR2) are currently rarely associated with AC. Four additional genes associated with 
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autosomal dominant arrhythmogenic right ventricular dysplasia (ARVD) have been mapped but not 
identified (locus names ARVD3, ARVD4, ARVD6, and ARVD7). Molecular genetic testing is clinically 
available for eight of the ten known genes (Table 1). Since ARVC is emerging a desmosome related 
disease (8 of 10 genes are desmosome related), desmosome gene mutations accounting for approximately 
50% of symptomatic individuals(48), and compound and digenic heterozygosity being often encountered, 
screening of all desmosomal ARVC related genes is now recommended(49). Among the different 
desmosome genes, mutations have been identified in desmoplakin (DSP), plakophilin-2 (PKP-2), 
desmoglein-2 (DSG-2), desmocollin-2 (DSC-2), junction plakoglobin (or gamma catenin) (JUP), and 
more recently in plakophilin-4 and desmin(50). 
Of note, mutations in some of these genes have been associated with genetically related (allelic) 
disorders. Specifically, RYR2 mutations have been identified in individuals with catecholaminergic 
polymorphic ventricular tachycardia (CPVT)(51)(52), as well as patients with "atypical" or "borderline" 
long QT syndrome (LQTS) who did not have mutations identified in the five genes associated with 
LQTS(53). DSP mutations can lead to Carvajal syndrome, an autosomal recessive disease characterized 
by ventricular dilated cardiomyopathy associated with keratoderma and woolly hair (54)(55)(56) (figure 
8), while JUP mutations can be causative of Naxos disease, an autosomal recessive form of ARVC 
characterized by palmoplantar keratoderma and peculiar woolly hair that was first observed on the island 
of Naxos, Greece(57). Historically, it was the phenotype of woolly hair and palmoplantar keratoderma in 
those two syndromes that pointed scientists towards screening desmosomal genes for pathogenetic 
mutations. Interestingly, as opposed to other ARVC subgroups, Naxos disease has full penetrance by 
adolescence(58). 
 
Ongoing efforts are aiming to identify genotype-phenotype correlations, with interesting preliminary. For 
example, compared with those without a desmosome gene mutation, individuals with a desmosome gene 
mutation had earlier-onset AC and were more likely to have ventricular tachycardia(59). Recent studies 
have also suggested that for rare desmosome gene mutations (namely, DSG2 and DSC2), the presence of 
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multiple mutations simultaneously may be required to manifest the ARVC phenotype and may be 
associated with increased disease severity, namely higher frequency of sudden death (60). 
 
Table 1. Arrhythmogenic right ventricular dysplasia (ARVD) gene loci. 
Disease locus Gene Name Gene Symbol Chromosome locus Frequency 
ARVD1 Transforming 
growth factor beta-3 
TGFB3 14q24 Rare 
ARVD2 ryanodine receptor 2 RYR2 1q42 Rare 
ARVD5 Transmembrane 
protein 43 
TMEM43 3p25 Unknown 
ARVD8 Desmoplakin DSP 6p24 6-16% 
ARVD9 plakophilin-2 PKP2 12p11 11-43% 
ARVD10 desmoglein-2 DSG2 18q12 12-40% 
ARVD11 desmocollin-2 DSC2 18q12 Rare 
ARVD12 junction plakoglobin 
(or gamma catenin) 
JUP 17q21 Rare 
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Figure 8. Deramological phenotype and genetic screening of a case of Cardiocutaenous syndrome 
(Carvajal). (A) Dystrophic nail plates. (B) Striate keratoderma of the palms. (C) Plantar keratoderma. (D) 
Erythemato-squamous skin lesions of the knee. (E) curly wooly hair. (F) Electropherograms of the 
desmoplakin mutation and of the wild type: a heterozygous variant in DSP, c.1748 T>C, was identified, 
resulting in the missense mutation p.Leu583Pro at a heterozygous state. 
Source: Keller D, et al,, ‘De Novo Heterozygous Desmoplakin Mutations Leading to Naxos-Carvajal 
Disease.’, Swiss medical weekly, 142 (2012). 
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Clinical Picture and task Force Criteria 
 Clinically, the patient usually presents with palpitations, due to premature ventricular complexes 
(PVCs) or nonsustained ventricular tachycardia. Other presentations are sustained ventricular tachycardia, 
syncope, resuscitated cardiac arrest, right heart failure or late stage biventricular heart failure(2). Multiple 
criteria are needed to diagnose ARVC, as there is no single gold standard criterion sufficiently specific to 
establish the diagnosis(58). Even the presence of desmosomal genetic abnormality is not sufficient as 
there is variable penetrance. However, it is important to note that the recessive form of ARVC (Naxos 
disease) presents full penetrance by adolescence, being associated with cutaneous abnormalities 
consisting of woolly hair and palmoplantar keratoderma(61). This diagnostic challenge led to the 
formation of an expert Task Force that in 1994 proposed major and minor criteria to aid in the 
diagnosis(62). The report achieved its goal of standardizing diagnostic criteria. With the growing 
International experience, an updated modified Task Force criteria (TFC) were published in 2010(11). The 
modified criteria include structural alterations observed by echocardiogram, cardiac magnetic resonance 
imaging and/or angiography. They also include tissue characterization of RV wall, repolarization 
abnormalities, depolarization abnormalities, arrhythmias, and family history (table 2). The modified 
criteria are also based on more quantitative analysis rather than the 1994 TFC qualitative nature. 
 
Table 2. Revised 2010 Task Force critiria for diagnosis of ARVC. Source: Marcus F, et al., ‘Diagnosis of 
Arrhythmogenic Right Ventricular Cardiomyopathy/dysplasia: Proposed Modification of the Task Force 
Criteria.’, European heart journal, 31 (2010), 806–14. 
1- Endomyocardial biopsy 
  
Major: 
 The total amount of the residual myocytes is less than 60% by morphometric analysis (or 
less than 50% if estimated), and the remaining of the free wall myocardium is replaced by 
fibrous tissue with or without fatty changes in more than one sample.  
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Minor :  
 The total amount of the residual myocytes is 60% to 75% by morphometric analysis (or 
50% to 65% if estimated), and the remaining of the free wall myocardium is replaced by 
fibrous tissue with or without fatty changes in more than one sample.  
 
2-Right ventricular structural and functional abnormalities  
 
A- Echocardiography  
Major :  
 Regional wall akinesia, dyskinesia, or aneurismal dilatation of the RV  
Plus one of the following: 
1) Right ventricular outflow tract of 19 mm/m2 in parasternal long axis view at the end 
diastole, 21 mm/m2 in parasternal short axis view at the end diastole  
2) RV fractional area change <33%.  
Minor :  
 Regional wall akinesia or dyskinesia  
Plus one of the following : 
1) Right ventricular out flow tract of 16 to19 mm/m2 in parasternal short axis view at the 
end diastole or 18 to 21 mm/m2 in parasternal short axis view at the end diastole  
 2) RV fractional area change 33-40%. 
 
B- Cardiac magnetic resonance 
Major : 
 Regional wall akinesia or dyskinesia or dyssynchronous contraction  
Plus one of the following: 
1) Ejection fraction less than 40%,  
2) End-diastolic volume t more than 110 mL/m2 ,or more 100 mL/m2 in males and 
females, respectively.  
Minor : 
 Regional wall akinesia or dyskinesia or dyssynchronous contraction  
plus one of the following: 
1) Ejection fraction less than 40%,  
2) End-diastolic volume t more than 110 mL/m2 ,or more 100 mL/m2 in males and 
females, respectively.  
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B- Right ventricular angiography 
Major : 
 ≥1 diskinetic, akinetic or aneurismatic right ventricular regions 
 
3- Electrocardiographic repolarization abnormalities 
 
Major :-  
 Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals >14 
years of age (in the absence of complete right bundle-branch block QRS>120 ms).  
 
Minor :- 
 Inverted T waves in leads V1 and V2 in individuals >14 years of age (in the absence of 
complete right bundle-branch block) or in V4, V5, or V6  
 Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of age in the 
presence of complete right bundle-branch block.  
  
4-Electrocardiographic depolarization abnormalities 
 
Major :  
 Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset 
of the T wave) in the right precordial leads (V1 to V3). 
 
Minor : 
 Late potentials by Signal Avereged ECG in >1 of 3 parameters in the absence of a QRS 
duration of >110 ms on the standard ECG: 
1) Filtered QRS duration (fQRS) >114 ms.  
2) Duration of terminal QRS ,40 mV (low-amplitude signal duration) >38 ms  
3) Root-mean-square voltage of terminal 40 ms <20 mV  
 Terminal activation duration of QRS >55 ms measured from the nadir of the S wave to 
the end of the QRS, including R0, in V1, V2, or V3, in the absence of complete right 
bundle-branch block.  
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5- Arrhythmias 
 
Major : 
 Non-sustained or sustained ventricular tachycardia of left bundle-branch morphology 
with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in 
lead aVL). 
 
Minor : 
 Non-sustained or sustained ventricular tachycardia of RV outflow configuration, left 
bundle-branch block morphology with inferior axis (positive QRS in leads II, III,and aVF 
and negative in lead aVL) or of unknown axis.  
 >500 premature ventricular beats per 24 hours (Holter). 
 
6. Family history/genetics 
 
Major : 
 Positive family history of first-degree relative confirmed by current task force criteria.  
 Pathological confirmation of the disease in first-degree relative either by autopsy or 
surgery.  
 Discovering of a DNA pathogenic mutation that has been recognized to be associated or 
probably associated with ARVC in the patient who has been evaluated for ARVC.  
 
Minor:  
 Positive family history of first-degree relative in whom the diagnosis is not feasible to be 
confirmed by current Task Force criteria.  
 Positive family history of young (<35 years) first degree relative with sudden death due to 
suspected ARVC.  
 Positive family history of disease in second degree relative who has been confirmed to 
have the disease either by current Task Force Criteria or pathologically. 
 
Diagnosis 
Established: At least two major criteria, one major criteria and three minor criteria, or four minor 
criteria from different categories 
Borderline:  One major criteria and two minor criteria, or three minor criteria from different 
categories 
Possible: One major criteria or two minor criteria from different categories 
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Electrocardiogram 
 The 12-lead electrocardiogram (ECG) is one of the most important tools for the diagnosis, 
follow-up and SCD risk stratification of AC (figure 9). Depolarization abnormalities due to activation 
delay as a result of cellular uncoupling and fibrofatty alteration include the epsilon wave, widening of the 
QRS complex (>110 msec) in leads V1 to V3 and evidence of late potentials by signal averaged ECG 
(SAECG). Epsilon wave is a defined as reproducible low amplitude signals between the end of the QRS 
complex to the onset of the T wave in the right precordial leads (V1-3). Although the epsilon wave is very 
specific for ARVC, Cox et al, showed that this parameter had a very low sensitivity (10%). Widening of 
the QRS complex was a criterion in 1994 TFC, but it was deleted in the 2010 TFC due to possible 
confusion especially in the presence of a right bundle branch block (RBBB). To overcome this confusion, 
many studies have proposed new ECG markers that focus on delayed RV activation in precordial leads. 
These include the presence of partial block(63), delayed S wave upstroke in V1-3 ≥55 msec(64), increased 
ratio of QRS duration in the right versus the left precordial leads(65), and a prolonged terminal activation 
duration ≥55 msec(66). Right precordial QRS prolongation and QRS dispersion have been significantly 
associated with an increase of the arrhythmic risk in patients with AC. In an important study, Turrini et 
al., showed a greater QRS prolongation (125 msec) in V1 to V2/V3 in AC patients with SCD, in 
comparison with living ARVC patients (113 msec). They also demonstrated that QRS dispersion of more 
than 40 msec (between the longest and shortest QRS intervals) was a strong predictor of SCD in 
ARVC(67). Abnormalities in repolarization in ARVC are represented as inverted T wave. Due to its high 
sensitivity, inverted T waves in V1-V3 or beyond in the absence of RBBB and in >12 year old individuals 
was upgraded from a minor criterion in the 1994 TFC to a major criterion in the 2010 TFC, for 
individuals older than 14 years and in absence of complete RBBB(11). The morphology of recorded 
ventricular tachycardia (VT) reflects its site of origin. In ARVC, affected areas in the triangle of dysplasia 
usually produce a VT with a left bundle branch block morphology and a superior axis, defined from -30
o
 
to -150
o
. Because of the variable extension of the disease, multiple VT morphologies are usually recorded 
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in a single patient. Studies showed the mean number of different VT morphologies per patient ranges 
from 1.8 to 3.8(68)(69). 
 
 
 
 
 
 
 
 
 
Figure 9. 12 Lead ECG of arrhythmogenic cardiomyopathy. Note the “epsilon wave” in V3, the right 
pericardial leads localized QRS prolongation which is mainly due to a terminal activation delay (from 
nadir of S to the end of QRS complex), and T wave inversion in V1-3. 
 
Echocardiography 
 Echocardiography is of paramount importance in the initial evaluation and follow up of ARVC 
patients because of its availability, ease of performance and interpretation, cost effectiveness and non 
invasive advantages (figure 10)(70). The multidisciplinary Study of Right Ventricular Dysplasia 
demonstrated that the diagnostic performance of transthoracic echocardiography was superior to MRI 
with 80% accuracy in affected individuals with AC and 40% accuracy in borderline individuals, 
compared with 49% and 15% for MRI, respectively (71)(72). RV outflow tract dilatation (in parasternal 
long axis view >32 mm or in parasternal short axis view >36 mm) coupled with localized anuerysms 
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(akinesia or dyskinesia) or global dysfunction (fractional area change <33%) is now considered a major 
criterion for the diagnosis of ARVC(11). Other echocardiographic features to assess RV anatomic 
alteration include the ratio between the RVOT/aorta in parasternal short axis view (abnormal if >1.2), 
longitudinal and transverse RV axes in apical four chamber and subcostal views, visualization of RV 
apical trabeculation in the subcostal view. Emerging echocardiographic techniques being currently 
evaluated include 3 dimensional echocardiography(73), RV free wall myocardial velocity, strain and 
strain rate by Doppler or speckle tracking (figure 11)(74)(75).  
 
Right Ventriculography 
 RV ventriculography remains an integral imaging modality and reference technique in the 
diagnosis and evaluation of patients with ARVC. This technique should be performed in all patients with 
suspected or definite ARVC and may be combined with electrophysiological study and/or RV 
endomyocardial biopsy. The angiographic diagnosis of ARVC is based on segmental abnormalities rather 
than diffuse RV enlargement or hypokinesia. Dedicated computer softwares for the evaluation of RV 
volume and regional wall motion have been developed and provide a convenient and reproducible method 
for quantitative assessment of global and regional RV contraction and relaxation(76)(77). 
 
Magnetic Resonance Imaging 
 Among the current cardiac magnetic resonance imaging (MRI) applications in cardiomyopathies, 
the greatest potentials and challenges are in the diagnosis of ARVC. Routinely used imaging planes are 
suboptimal for RV evaluation, and the technique of ARVC imaging involves unconventional imaging 
planes. Furthermore, the lack of familiarity of the MRI interpreters with RV contraction pattern and the 
normal epicardial fat distribution pose challenges for accurate and reproducible reporting. 
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Figure 10. Echocardiography of a patient with arrhythmic cardiomyopathy. Upper panel shows an apical 
4 chamber view with dilated anuerysmal right ventricle. Lower panel shows a modified short axis left 
paraternal view to visualize the subtricuspid area which shows a localized aneurysm. 
(Images courtesy of MP Marra, MD, University of Padua, Italy). 
 
Also, it requires a high degree of expertise to accurately differentiate ARVC from alternative diseases 
with similar MRI picture -especially late gadolinium enhancement (LGE)- such as myocarditis and 
sarcoidosis(78). Finally, over-reliance on the presence of intramyocardial fat has resulted in a high 
frequency of misdiagnosis of ARVC(79). Despite of these limitations, cardiac MRI has emerged as a 
robust tool to evaluate ARVC patients (figure 12). It has the ability to noninvasively provide tissue 
characterization for detection of fat and more importantly fibrosis in the RV, and also the LV. 
Quantitative data on ventricular volumes, functions, and regional contraction abnormalities are useful in 
the diagnosis and follow up of patients with ARVC(80). MRI studies have also helped in genotype-
phenotype correlation of ARVC; LV involvement is rare in PKP 2 mutation but more common in 
desmoplakin and plakoglobin mutation carriers(33)(81). 
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Figure 11. Apical 4-chamber view with 2D speckle imaging of the LV septum and RV free wall in a 
normal older patient. The images display longitudinal velocity (A), strain (B), strain rate (SR) (C), and 
displacement (D) curves. A', Late diastolic waveform; AR, apical right ventricle; AS, apical septum; BR, 
basal right ventricle; BS, basal septum; E', early diastolic waveform; MR, mid right ventricle; MS, mid 
septum; S', systolic waveform. 
Source: Horton K, Meece R, Hill R, ‘Assessment of the Right Ventricle by Echocardiography: a Primer 
for Cardiac Sonographers.’, Journal of the American Society of Echocardiography, 22 (2009), 776–92. 
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Figure 12. Cardiac magnetic resonance imaging of a patient with extensive AC. Short axis view from 
base (upper left) to apex (lower right) demonstrating extensive fibrosis as evidenced by delayed 
gadolinium enhancement in most of right ventricular wall (only sparing a small infero-septal area), 
interventricular septum and the epicardium of the left ventricular inferior wall. This patient underwent 
cardiac transplantation for severe right heart failure. (Images courtesy of MP Marra, MD, University of 
Padua, Italy) 
 
Electrophysiological mapping and Ablation 
 Three dimensional electro-anatomic mapping has helped in understanding the substrate and 
mechanisms underlying VT in ARVC patients. Electrical activation through normal RV myocardium was 
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defined in patients with no structural heart disease with the use of the CARTO electro-anatomic mapping 
system and the Navistar catheter (Biosense Webster, Diamond Bar, CA, USA), which has a 4-mm distal 
tip electrode, and a 1-mm inter-electrode distance. Normal RV endocardium is characterized by bipolar 
signals displaying 3 or fewer deflections from baseline, with peak to peak amplitude greater than 1.5 mV, 
whereas areas of bipolar voltage less than 0.5 mV correspond to dense scar, i.e., EAS. RV bipolar EAS 
was demonstrated to correlate with the histopathologic finding of fibrofatty myocardial replacement at 
endomyocardial biopsy in AC patients(8)(9). Corrado and colleagues demonstrated that electrovoltage 
mapping enhances the diagnostic specificity of ARVC by distinguishing between pure genetically-
determined ARVC, which is characteristically associated with EAS involvement, and acquired RV 
inflammatory cardiomyopathy, mimicking AC but showing a preserved electrogram voltage and a better 
prognosis(8)(9). Moreover, electrovoltage mapping has been proven to increase diagnostic sensitivity for 
early/minor form of AC underlying apparently idiopathic RVOT tachycardias, by detecting otherwise 
concealed segmental RV EAS areas in the RVOT, which are associated with a worse arrhythmic 
outcome(9). Finally, EVM has been recently reported to be significantly more sensitive than contrast-
enhancement-cardiac magnetic resonance in identify RV scar lesion (figure 13)(82). In accordance with 
the pathological findings concerning the progress of the fibrofatty dystrophy from the epicardium towards 
the endocardium; Garcia et al demonstrated that most patients with AC have a far more extensive 
substrate for VT using epicardium mapping than they do on RV endocardium(83). Due to the 
disappointing initial results endocardial ablation results(84), VT ablation as a line of therapy for patients 
with ARVC has been considered only in patients with end-stage ARVC, incessant VT, frequent 
implantable cardioverter defibrillator (ICD) interventions and intolerable antiarrhythmic drugs side-
effects. However, more promising results have been recently published using more aggressive and 
sophisticated endocardial and epicardial substrate mapping and ablation techniques(83)(85). Yet, those 
results, being exclusive to very highly experienced centers, may be difficult to reflect in general practice.  
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Figure 13. (A) Bipolar endomyocardial electrovoltage mapping of a patient with arrhythmogenic 
cardiomyopathy. Red color represents areas of a low voltage recordings ˂0.5 mV indicating a dense scar 
tissue. (B) Cardiac magnetic resonance of the same patient. Extensive fibrotic changes demonstrated by 
delayed gadolinium enhancement in most of the right ventricular free wall and extending into the 
interventricular septum (concordant to the electrovoltage mapping findings). 
(Images courtesy of MP Marra, MD, University of Padua, Italy) 
 
Pharmacological Therapy 
 Pharmacological treatment has been another challenging aspect in ARVC, given the small 
number of patient study populations and the near lack of randomized clinical trials. One of the largest 
series of pharmacologic therapy in AC is from Germany, first published in 1992 and updated in 2005 with 
191 patients and 608 drug tests(86)(87). Sotalol at a dosage of 320-480 mg/d was the most effective drug 
resulting in a 68% overall efficacy. Combinations of amiodarone and beta-blockers were also efficacious. 
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Another large study was presented from the North American Registry in 2009(88). Of 108 patients in this 
registry, it was concluded that there was no clinically significant benefit in preventing malignant 
ventricular arrhythmias with beta-blockers. However there was a trend in the reduction in number of 
shocks in patients with implantable cardioverter defibrillator (ICD) and on a beta-blocker therapy. In 
opposition to the German registry, sotalol failed to show any clinical benefit, with worse outcomes 
associated with highest doses of sotalol. A small number (10 patients) were studied for amiodarone, and 
they showed 75% lower risk of any clinically relevant ventricular arrhythmias compared with all other 
patients. The mixed results from those two registries lead to the conclusion that there is not sufficient 
evidence to adequately guide physicians considering pharmacological management of ARVC(89). 
 
Implantable Cardioverter Defibrillator 
 There is accumulating evidence that ICD provides life saving protection by effectively 
terminating ventricular arrhythmias in high risk patients with AC, coining ICD therapy as the gold 
standard line of management for those patients. One of the most seminal mutli-center studies of ICD 
therapy in ARVC is the DARVIN I study. The study was published in 2003, with a study population of 
132 ARVC patients, 80% of them received ICD implant because of a history of either cardiac arrest or 
sustained VT (secondary prevention). Over the study period of 39 ±25 months, 3 deaths occurred (only 
one SCD; one for infective endocarditis and one for heart failure), 48% of patients (64 out of 132) had at 
least one appropriate ICD intervention. Fifty three of the 64 patients were receiving antiarrhythmic 
medication at the time of the first appropriate shock. Twelve percent of the patients received inappropriate 
ICD interventions and 16% had ICD-related complications (figure 14)(90). This was followed by the 
mutli-center DARVIN II study which focused on primary ICD prevention in high risk AC patients. The 
study included 106 patients with AC and no prior VF or VT who received an ICD because of one or more 
arrhythmic risk factors such as syncope, asymptomatic nonstained VT, familial SCD and inducibility of 
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sustained VT by programmed ventricular stimulation in the electrophysiological laboratory. During a 
mean follow up of 4.8 years, no death occurred, and 24% of the patients received appropriate ICD 
interventions and 19% received inappropriate interventions(91). In another large single center study, 
Witcher et al., reported 60 ARVC patients who received ICD therapy and were followed up for a period 
of 80±43 months. The majority of the cases received their ICD as a secondary prevention. With only 26% 
of event free follow up in the highest risk group, the study confirmed the improvement of long term 
prognosis of high risk AC patients who undergo ICD implantation(92).  
 
 
 
Figure 14. DARVIN I Kaplan-Meier analysis of actual patient survival (upper line) compared with 
survival free of ventricular fibrillation/flutter (lower line) that in all likelihood would have been fatal in 
the absence of the ICD. The divergence between the lines reflects the estimated mortality reduction by 
ICD therapy of 24% at 3 years of follow up. 
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Source: Corrado D, et al., ‘Implantable Cardioverter-defibrillator Therapy for Prevention of Sudden 
Death in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy/dysplasia.’, Circulation, 108 
(2003), 3084–91. 
 
Sports and Pre-participation Screening 
 The cornerstone in the management of ARVC as a cause of SCD relies on screening among high 
risk population. Corrado et al., have shown that the risk of sudden death from AC has been estimated to 
be 5.4 times greater during competitive sports than during sedentary activity (figure 15).(29) This can be 
attributable to the fact that physical exercise acutely increases the RV afterload and causes cavity 
enlargement, which in turn may elicit ventricular arrhythmias by stretching the diseased RV myocardium. 
This theory has been confirmed by Kirchof et al., in an experimental study on heterozygous plakoglobin-
deficient mice, when compared with wild-type controls, the mutant mice had increased RV volumes, 
reduced RV function, and more frequent and severe VT of RV origin. Endurance training accelerated the 
development of RV dysfunction and arrhythmias in the plakoglobin-deficient mice(93). For more than 30 
years a systemic pre-participation screening for athletes, based on 12-lead ECG, in addition to history and 
physical examination, has been in practice Italy. A time trend analysis of the incidence of SCD in athletes 
aged 12 to 35 years in the Veneto region in Italy between 1979 and 2004 has proved compelling evidence 
of the efficiency of this life saving screening strategy. The annual incidence of SCD in athletes decreased 
by 89% from 3.6 per 100,000 during the prescreening period to 0.4 per 100,000 in the late screening 
period (figure 16)(94). This is highly attributable to the efficiency of ECG in detecting HCM and AC as 
the most common causes of SCD amongst athletes. Moreover, during long term follow-up, no deaths 
were recorded in the disqualified athletes with HCM, suggesting that restriction from competition may 
reduce the risk of SCD(95). 
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Electrogenesis of T wave inversion  
  The T wave corresponds to repolarization of the ventricle and it is an electric manifestation of a 
normally asymmetrical repolarization process. An important electrocardiographic parameters obtained 
from body surface ECG, the Tpeak-to-end (Tp-e) interval and T wave inversion, have been shown to be a 
predictor of arrhythmias under a variety of clinical situations(96)(97)(98)(99). However, the 
electrogenesis of T wave and its pathological variants has been the subject of a long historical debate. 
In 1883, Burdon-Sanderson and Page were the first to demonstrate that in the frog’s heart, the wave of 
excitation spreads from the base to the apex of the ventricle(100). The record was diphasic, with the first 
positive (R) wave followed by a negative (T) wave. They also demonstrated that the T wave corresponds 
to repolarization of the ventricle. Similar series of experiments by Bayliss and Starling in 1892 in the 
canine heart showed that the T waves are usually upright in mammals(101). This was followed by Mines 
on frog’s heart using Einthoven’s String Galvanometer in 1913(102).  
 
 
Figure 15. Incidence and relative risk (RR) of sudden death (SD) for specific cardiovascular causes 
among athletes and non-athletes. ARVC: arrhythmogenic right ventricular cardiomyopathy; CAD: 
coronary artery disease; CCA: congenital coronary artery anomaly; MVP: mitral valve prolapse. 
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Source: Corrado D, et al., ‘Does Sports Activity Enhance the Risk of Sudden Death in Adolescents and 
Young Adults?’, Journal of the American College of Cardiology, 42 (2003), 1959–63. 
 
Mines stated that the T wave is an electric expression of asymmetrical passing off of excitation 
(repolarization) in different parts of the ventricles and that the polarity of the T wave can be predicted by 
changing the duration of the action potential in a controlled manner. In 1931, Wilson et al. put forward 
the hypothesis that the concordance of the T wave with the R wave on the surface ECG can be explained 
by assuming that the depolarization and the repolarization waves must travel in opposite directions at 
least in some parts of the ventricle(103). The biophysical principle behind this hypothesis requires that the 
cells that activate first have to repolarize last to produce a T wave of the same polarity of that of the R 
wave. In other words, the action potential duration (APD) in the cells that are excited first should be 
significantly longer than the cells that are excited last. 
 
 
Figure 16. Annual incidence rates of SCD per 100,000 person-years among screened competitive athletes 
and unscreened nonathletes aged 12 to 35 in Veneto region, Italy. Note the sharp decline of the screened 
athlete graph. 
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Source: Corrado D, et al., ‘Trends in Sudden Cardiovascular Death in Young Competitive Athletes After 
Implementation of a Preparticipation Screening Program.’, JAMA : the journal of the American Medical 
Association, 296 (2006), 1593–601. 
 
In an attempt to explain the positive polarity of the T wave in mammals, Noble and coworkers in 1976 
recorded action potentials from tissue slices dissected from the “base” and the “apex” of the sheep 
ventricle and showed that at steady state, APD is longer at the “base” as compared with the “apex”.  
They concluded that such a difference could account for a positive polarity of the T wave in 
mammals(104). This series of experiments laid down the foundation of the controversial hypothesis that 
apico-basal difference in the time course of repolarization underlies the genesis of a positive T wave. The 
theory of apico-basal dispersion of repolarization as a basis of the electrocardiographic T wave dominated 
the medical literatures until the 1990s when the discovery of M cells, and the development of the left 
ventricular wedge technique suggested that the transmural dispersion of repolarization may 
contribute importantly to the genesis of the T wave(105)(106)(107)(108)(109). An increasing number of 
studies have shown that the ventricular myocardium is not a homogeneous structure, but it is comprised 
of 3 distinct cell types, i.e., epicardial, subendocardial and endocardial cells, with clearly distinct 
electrophysiological and pharmacological properties. The M cells are located in deep subendocardium of 
the canine LV(105)(106). The hallmark of M cells is the ability of its action potential to prolong more 
than that of the epicardium or endocardium in response to slowing of the rate or in response to agents that 
prolong APD. The development of the canine and rabbit left ventricular wedge models have provided the 
ability to record transmembrane action potentials from 3 different myocardial cell types simultaneously 
(figure 17). The presence of an important transmural repolarization gradient in ventricle has been well 
established in a variety of species. This model coupled with mathematical simulations of the myocardium 
35 
 
provide evidence in support of a predominant role for the transmural voltage gradient in the genesis of the 
T wave(110)(111).  
Despite the remarkable ability of wedge preparation to reproduce the electrocardiographic and arrhythmic 
manifestations of a wide variety of syndromes observed in clinical practice, it has its limitations. Some 
argue that the canine left ventricular wedge is too small a sample and does not reflect what might happen 
in an intact heart(112). In fact, refuters of the transmural gradient theory point to that only in one study 
study of El-Sherif et al, a small prolongation of activation-recovery intervals in midmural regions was 
found in young dogs, albeit only at long cycle lengths(113). In the human heart, several series could not 
find a transmural gradients in activation-recovery interval or repolarization times (114)(115). 
Furthermore, an analysis of the data from the study on monophasic action potential mapping in humans 
by Franz et al showed that epicardial repolarization occurred later than endocardial repolarization 
(116)(117). In addition, in the study of Chauhan et al, repolarization time in the anteroseptal right 
ventricular endocardium in cardiomyopathy patients without arrhythmias was on average 288 ms, and left 
ventricular epicardial repolarization time adjacent to the septum was 287 ms, demonstrating no significant 
gradient between the endocardium and epicardium (118). Although the exact mechanism for the genesis 
of T wave abnormalities on the surface ECG remains a matter of scientific controversy, their clinical 
utility as an index of arrhythmogenesis and prognostic outcome in cardiomyopathies is gaining increasing 
recognition(119). 
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Figure 17. (A) The cellular basis of the T wave in the canine left ventricular wedge preparation. 
Simultaneous recordings of action potential with of 3 different cell type with a pseudo-ECG are shown. 
Note that the opposing voltage gradient on either side of the M region leads to inscription of the T wave. 
The peak of the T wave coincides with the end of repolarization of the epicardial cell and the end of the T 
wave coincides with the end of repolarization of the M cells. (B) The cellular basis of the T wave in the 
rabbit left ventricular wedge. In the rabbit, the entire endocardium has the same electrophysiological 
properties as M cells. Therefore, the end of the T wave coincides with the end of repolarization of the 
endocardium in the rabbit. Epicardial pacing leads to earlier activation of epicardial cells with shorter 
APD and delays the activation of endocardial cells with a longer APD, leading to an increase in QT and 
Tp-e interval. Epi Epicardium; Endo, Endocardium; AP, action potential. 
Source: Yan G and Antzelevitch C, ‘Cellular Basis for the Normal T Wave and the Electrocardiographic 
Manifestations of the long-QT Syndrome.’, Circulation, 98 (1998), 1928–36. 
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AIM OF THE WORK 
To assess the prognostic value of the presence and extent of electroanatomical scar detected by 
endocardial voltage mapping in patients with arrhythmogenic right ventricular cardiomyopathy and to 
evaluate the non invasive predictors of the electroanatomical scar size. 
To study the exercise-induced right precordial negative T wave changes in patients with arrhythmogenic 
right ventricular cardiomyopathy 
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METHODS AND RESULTS 
 
Non-invasive predictors of electroanatomic scar size in arrhythmogenic right 
ventricular cardiomyopathy 
 
Methods 
 
Study Population 
The study population included 69 consecutive patients (47 males; median age 35 years [28–45]) with 
ARVC/D who were referred at the Division of Cardiology of the University of Padova, Italy for risk 
stratification. All patients underwent detailed cardiac evaluation including family history, physical 
examination, 12-lead ECG recording, signal-averaged ECG; 24-hour Holter monitoring, exercise stress 
testing, echocardiography and cardiac catheterization including RV and left ventricular (LV) angiography 
in the right and left anterior oblique view, and coronary angiography.  
All patients met the International Task Force (ITF) criteria (2 major criteria or 1 major criterion plus 2 
major criteria or 4 minor criteria) for diagnosis of definite ARVC Diagnosis was established according to 
the original ITF criteria(62) and confirmed using the recently revised criteria(11). All patients underwent 
intracardiac electrophysiological study with PVS for assessing VT/VF inducibility and high density EVM 
for imaging and quantification of abnormal RV EVM. A subanalysis focused on the group of patients 
who had showed an abnormal EVM with evidence of ≥1 RV-EAS to assess the noninvasive features that 
correlate best with the presence and the extent of the EAS. The study was approved by the institutional 
review board, and all patients gave their informed consent. 
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Echocardiogram  
Echocardiograms were obtained using a 2.5- to 4-MHz transducer (Hewlett Packard model 5500, 
Andover, Massachusetts) and included M-mode, 2-dimensional, and Doppler examinations. Parasternal, 
apical and subcostals views were performed to evaluate the presence of right-ventricular wall motion 
abnormalities. Right ventricular end-diastolic volumes (RV-EDV) was calculated using an area-length 
method derived from orthogonal planes (apical 2-chamber and short-axis subcostal views). Right 
ventricular fractional area change (RV-FAC) was derived from the calculated systolic and diastolic RV 
areas on apical 4-chamber view. Left ventricular (LV) end-diastolic volume, end-systolic volume and 
ejection fraction were calculated using the Simpson's method. 
 
12-lead ECG and SAECG 
ECGs were evaluated on standard speed paper. The following ECG abnormalities were analyzed:  
 low QRS voltage in limb leads (≤0.5 mV) 
 QRS duration ≥110 msec in V1-V3 
 delayed S-wave upstroke in leads V1 to V3 (> 60 msec from nadir of S wave to baseline) in the 
absence of complete right-bundle branch block 
 epsilon waves (defined as reproducible low amplitude signals between end of QRS complex to onset 
of the T-wave in the right precordial leads V1-V3 
 left axis deviation (< -30°) 
 right axis deviation (> 90°)  
 T-wave inversion ≥1 mm in depth in ≥2 adjacent leads.  
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Three patients had complete right bundle branch block and were excluded from analysis of repolarization 
abnormalities.  
SAECGs were obtained using a MAC15 system (Marquette Inc., Milwaukee, Illinois). The following 
parameters were evaluated for each filter (25 and 40 Hz): 
 filtered QRS duration (fQRSD) 
 duration of the low-amplitude signals (<40 mV) in the terminal portion (LAS-40) 
 root mean square voltage of the last 40 ms (RMS-40).  
According to the 2010 Revised International Task Force Criteria for ARVC, ventricular late potentials 
were considered present when 1 or more of the following criteria were fulfilled: 1) fQRSd ≥114 ms; 2) 
LAS-40 ≥38 ms; 3) RMS-40 ≤20 uV (11). 
 
Electrophysiological Study 
All antiarrhythmic drugs were discontinued 5 half-lives (6 weeks for amiodarone) before the 
electrophysiological study. Programmed ventricular stimulation protocol included 3 drive cycle lengths 
(600, 500, and 400 ms) and 3 ventricular extrastimuli while pacing from 2 RV sites (apex and outflow 
tract). Programmed ventricular stimulation was considered positive if either a VF or sustained VT (i.e., 
one that lasted ≥30 seconds or required termination because of hemodynamic compromise) was induced. 
Programmed ventricular stimulation was repeated after intravenous isoproterenol infusion in those 
patients with effort induced non sustained VT (16 of 53, 26%). 
 
Electroanatomic Voltage Mapping 
At the time of electrophysiological study, all patients underwent detailed EVM by the CARTO system 
(Biosense-Webster) during sinus rhythm. A 7-F Navi-Star (Biosense- Webster) catheter, with a 4-mm 
distal tip electrode and a 2-mm ring electrode with an interelectrode distance of 1 mm, was introduced 
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into the RV under fluoroscopic guidance and used as the mapping/ ablation catheter. The catheter was 
placed at multiple sites on the endocardial surface of RV free wall (infero-basal, antero-lateral free wall, 
apex, and RV outflow tract) and septum to reconstructed the 3-dimensional geometry of the RV chamber. 
Bipolar electrogram signals (filtered at 10–400 Hz and displayed at 100 mm/s speeds on the CARTO 
system) and unipolar signals (filtered at 1–240 Hz and displayed at 100 mm/s speeds on the CARTO 
system) were recorded and analyzed simultaneously with regard to amplitude, duration, relation to the 
surface QRS, and presence of multiple components. Duration of an endocardial bipolar electrogram was 
measured as the time from the earliest electric activity to the artifact produced by the decay of the 
amplified filtered signal. Bipolar signals were recorded between the distal electrode pair, unipolar signals 
between the distal tip of the ablation catheter (cathode) and the Wilson central terminal. In our study the 
following tools were used to avoid false low voltage recordings:  
adequate catheter contact was confirmed by concordant catheter tip motion with the cardiac silhouettes on 
fluoroscopy 
a recording was accepted and integrated into the map when the variability in cycle length, local activation 
time stability, and maximum beat-to-beat difference of the location of the catheter (automatically detected 
by the CARTO system) were <2%, <3 ms, and <4 mm, respectively (these parameters, combined with the 
stability of the impedance reading, were used to exclude low amplitude signals attributable to poor 
endocardial catheter contact) 
in the presence of a low voltage area, ≥3 additional points were acquired in the same area to confirm the 
reproducibility of the voltage measurement.  
Particular attention was paid to validate the acquisition of endocardial points from the RV infero-basal 
region, because of the recognized risk of poor tissue contact in this area. Because of the potential high 
mapping error and to avoid overestimation of low voltage RV areas resulting from inclusion of normal 
annular fibrous tissue, the immediate perivalvular areas (ie, within 1.5 cm of the valvular locations on 
postprocessing measurement) were excluded in the analysis of endocardial low voltages. 
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Values of normal RV endocardial voltages were established by RV EVM in 6 reference patients without 
structural heart disease, who underwent electrophysiological study for evaluation of supraventricular 
tachycardia. RV septal endocardial sites (23±5) were excluded and only RV free-wall electrogram 
recordings (207±16 points sampled), either bipolar or unipolar, were analyzed. Normal bipolar 
electrograms were sharp with ≤3 rapid deflections; the mean electrogram duration was 34.8±1.2 ms and 
the mean amplitude 5.3±0.9 mV, with 95% of all electrogram signals <66 ms and >1.47 mV. In addition, 
we analyzed the amplitude of unipolar electrograms, which was 10.3±0.6 mV with 95% of all unipolar 
signals recorded having an amplitude >5.96 mV. Then in the present study the reference values used to 
define normal RV electrogram amplitude was set at 1.5 mV for bipolar signals and 6.0 mV for unipolar 
signals, which were the values above which 95% of all bipolar and unipolar electrogram voltages from 
the endocardium of normal RVs were included. 
We considered normal bipolar electrocardiograms those with sharp and ≤3 spikes, amplitude >1.5 mV, 
and duration ≤70 ms. We defined as fragmented electrograms those characterized by multiple deflections 
(>3), amplitude ≤1.5 mV, and duration >70 ms. Normal amplitude electrograms (bipolar >1.5 mV and 
unipolar >6.0 mV) were represented in the electroanatomic CARTO map by the color purple, whereas 
low-amplitude signals were represented by non-purple range of colors. Color red indicated dense scar, 
which was arbitrarily defined as bipolar signal amplitude <0.5 mV and unipolar signal amplitude <3.5 
mV, according to previously reported criteria. 20–24 An EVM was considered abnormal in the presence 
of a single or multiple RV low voltage areas ≥1 cm2 including ≥3 adjacent points with a bipolar signal 
amplitude <1.5 mV and an unipolar signal amplitude <6.0 mV. 
Complete endocardial maps were obtained in all patients to ensure reconstruction of a 3-dimensional 
geometry of the RV chamber and to identify areas of abnormal electrograms in the RV free wall. The 
septum was excluded from the analysis. Regions showing low-amplitude signals were mapped with 
greater point density to delineate the extent and borders of endocardium electroanatomic scar areas. The 
extent of low-voltage areas was estimated by using a CARTO incorporated area calculation software 
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(CARTO, Biosense Webster Inc. Diamond Bar, CA) and was expressed both as total RV area and 
percentage of RV area, excluding tricuspid and pulmonary valvular annuli. 
 
Follow-Up 
The follow-up data were obtained prospectively during regular outpatient visits at 6- to 12-month 
intervals. Routine ICD interrogation and ECG recordings at the time of symptoms were used to document 
the occurrence of spontaneous VT during follow-up. The study outcome was the index combined end 
point of major arrhythmic events such as sudden death (SD), cardiac arrest attributable to VF, sustained 
VT, or appropriate ICD intervention. Sudden death was defined as any natural death occurring 
instantaneously or within one hour from symptoms onset. Sustained VT was defined as tachycardia 
originating in the ventricle with rate >100 beats/min and lasting >30 seconds or requiring an intervention 
for termination. Appropriate ICD intervention was defined as a device shock or antitachycardia overdrive 
pacing delivered in response to a ventricular tachyarrhythmia and documented by stored intracardiac ECG 
data. Ventricular fibrillation and VT were defined as a ventricular tachyarrhythmia with a cycle length 
≤240 ms or >240 ms respectively. Implantable cardioverter defibrillator were routinely programmed to 
include a monitoring zone that identified VT with a rate >160 bpm. 
 
Statistical Analysis 
Results are summarized as mean±standard deviation (SD) or median with 25 to 75 percentiles for 
normally distributed and skewed variables, respectively. Normal distribution was assessed using Shapiro–
Wilk test. Categorical differences between groups were evaluated by the χ2 test of the Fisher exact test as 
appropriate. Paired and unpaired t tests were used to compare normally distributed continuous variables 
respectively obtained from the same patient and different patients; paired and unpaired Rank Sum test 
were used for skewed continuous variables. Kaplan–Meier analysis was used to estimate the survival 
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distributions of the index combined end point and to show the difference in survival between patients 
with normal versus abnormal bipolar EVM and positive versus negative PVS. Start of follow-up was 
defined as the date of the initial EVM. Patients were censored at the time of their first event or the time of 
their last clinical follow-up. The mean event rate per year was evaluated by the number of events 
occurring during the follow-up divided by the number of patients multiplied by the average duration of 
follow-up. The independent correlation of traditional clinical predictors of arrhythmic risk in ARVC/D 
with the index combined end point during follow-up was determined by means of univariate and 
multivariable Cox regression analysis. Variables with a probability value <0.15 were integrated into 
multivariable analysis using Cox proportional-hazard models to estimate the Hazard ratio (HR) and to 
identify independent predictors of major arrhythmic events. The Cox model was used to calculate 
the relation between amount of RV low-voltage areas and hazard ratios. HRs and confidence intervals 
(CI) are presented both in univariate and multivariable analysis. The c-statistic method was used to 
estimate the best cut-off value of bipolar low-voltage area to discriminate between patients with and those 
without major arrhythmic events during follow-up.  
For the sub-analysis of EAS-positive patients, the Spearman’s correlation coefficient (rho) was used for 
correlating RV-EDV and RV-FAC with the EAS area. The Spearman coefficient ranges from ±1 (perfect 
correlation) to 0 (no correlation). The Kruskal Wallis test was used for testing the association between the 
extent of negative T-waves across the 12 leads and RV-EAS% area. Variables associated with the EAS 
area at univariate analysis with a p value < 0.1 were integrated into a multivariate linear regression model. 
The regression coefficient B is defined as the expected change in the dependent variable (RV-EAS% 
area) for a one-unit change in the independent variable. Event-free survival curves were drawn with the 
Kaplan-Meier
 
method and compared by the logrank test. A value of P<0.05 was considered significant. 
Statistics were analyzed with SPSS version 17 (SPSS Inc, Chicago, IL). 
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Results 
 
Clinical Characteristics 
Baseline clinical characteristics and instrumental findings are summarized in Table 3. The study 
population included 69 consecutive patients (47 men; median age, 35 years [28–45]). 
Twenty-eight patients (40%) had a family history of ARVC (n=12, 17%) or premature (<35 years) sudden 
death (n=16, 23%). Twenty-two (32%) patients had a history of cardiac arrest or syncope. Ventricular 
tachycardias were documented in 53 (76%) patients and included sustained VT (n=9, 13%) or 
nonsustained VT (n=44, 63%). There were 15 morphologies of sustained VT, all with a left bundle branch 
pattern, with a superior axis in 8, inferior axis in 4, and undetermined axis in 3. Right ventricular 
dilatation/dysfunction was observed at echocardiography/angiography in all patients. Multiregional 
wall motion abnormalities (akinesia, diskinesia or bulging involving ≥2 RV regions) were found in 25 
(36%) patients. Thirty-four (49%) patients were inducible at programmed ventricular stimulation to either 
sustained monomorphic VT (n=23) or VF (n=11). Among 8 noninducible patients, 2 experienced exercise 
induced arrhythmic events during follow-up. At enrolment, 57 (82%) patients with VT or frequent 
premature ventricular beats were empirically treated with antiarrhythmic drug therapy, which consisted of 
sotalol (n=22), amiodarone either alone (n=9) or in combination with beta blockers (n=14), beta blockers 
(n=7), and flecainide (n=5). 
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Table 3.Clinical characteristics of overall sample and according to results of bipolar-EVM. 
 
* multiregional WMA=akinesia, diskinesia or bulging in ≥2 RV regions 
ARVC/D=arrhythmogenic right ventricular cardiomyopathy/dysplasia; EDV=end diastolic volume; 
EF=ejection fraction; FAC=fractional area change; LV=left ventricle; PVS=programmed ventricular 
stimulation; RV=right ventricle; SAECG=signal averaged electrocardiogram; SD=standard deviation; 
VT=ventricular tachycardia; WMA=wall motion abnormalities. 
 Overall 
sample 
N = 69 
Abnormal 
bipolar-EVM 
N = 53 (77%) 
Normal 
bipolar-EVM 
N = 16 (23%) 
 
P 
Age (yrs), (mean ± SD) 37.3±13.6 37.4±12.8 37.3±16.4 0.42 
Sex (male), n (%) 47 (68) 36 (68) 11 (69) 1.00 
Family history of sudden death (<35 years), n (%) 
Family history of ARVC/D, n (%) 
16 (23) 
12 (17) 
15 (28) 
11 (20) 
1(6) 
1(6) 
0.12 
0.34 
History of cardiac arrest or syncope, n (%) 
Right precordial T-wave inversion (V1-V3), n (%) 
Positive SAECG, n (%) 
Premature Ventricular Beats > 1000/24 hours 
Non-sustained VT, n (%) 
Sustained VT, n (%) 
22 (32) 
49 (71) 
34 (49) 
59 (85) 
44 (63) 
9 (13) 
20 (37) 
41 (77) 
29 (54) 
45 (85) 
33 (62) 
8 (15) 
2 (12) 
8 (50) 
5 (31) 
15 (94) 
11 (69) 
1 (6) 
0.07 
0.04 
0.13 
0.72 
0.81 
0.72 
RVEDV (ml/m2, mean ± SD) 
RVFAC (%, mean ± SD) 
LVEDV (ml/m2, mean ± SD) 
LVEF (%, mean ± SD) 
Multiregional RV-WMA*, n (%) 
85±31 
36±6 
67±17 
57±10 
25 (36) 
87±34 
36±6 
67±15 
56±10 
22 (41) 
76±18 
37±7 
67±22 
58±6 
3 (19) 
0.09 
0.82 
0.94 
0.26 
0.01 
Inducibility at PVS, n (%) 
- VT, n (%) 
- VF, n (%) 
34 (49) 
28 (41) 
6 (9) 
26 (49) 
22 (42) 
4 (8) 
8 (50) 
6 (38) 
2 (13) 
1.00 
0.93 
0.91 
ICD implantation, n (%) 31 (44) 29 (54) 2 (12) 0.004 
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Electroanatomic Voltage Mapping  
Endocardial voltage mapping was successfully acquired during sinus rhythm in all patients, with a mean 
number of sites sampled of 195±22. 
 
Bipolar EVM 
An abnormal bipolar RV EVM was recorded in 53 (77%) patients. Patients with and without evidence of 
abnormal bipolar EVM had similar baseline clinical characteristics, except for multiregional RV wall 
motion abnormalities, which was significantly more prevalent in the abnormal bipolar EVM group. In 
patients with an abnormal bipolar EVM the median RV low-voltage area was 39.1 cm2 (13.2–67.8) with 
a median percent RV area of 24.8% (7.2–31.5; Figure 18). The involved RV regions were infero-basal in 
49 (71%) patients, antero-lateral in 28 (40%), RV outflow tract in 25 (36%), and apex in 15 (22%) 
(Figure 19). 
Mean bipolar amplitude of local electrograms recorded from within RV electroanatomic scar areas was 
significantly lower than that sampled from unaffected RV areas (0.38±0.11 vs. 5.2±0.6mV; P<0.001). 
Similarly, bipolar electrograms from low-voltage areas had a longer mean duration (78.9±18 vs. 
33.5±7.8ms; P<0.001) and more often extended beyond the offset of the surface QRS (64% vs. 7%; 
P<0.001), compared with electrograms sampled from regions with preserved electrogram voltage (Figure 
20). Fragmented bipolar electrograms (i.e., signals with > 3 deflections, amplitude ≤1.5 mV, and duration 
>70 ms) were recorded in 47 of 53 (88%) patients with an abnormal bipolar EVM. In 16 patients (23%), 
EVM was normal, with preserved bipolar endocardial electrogram amplitude (4.8±1.3 mV) and duration 
(35.3±0.8 ms). 
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Unipolar EVM 
In the 53 patients (77%) with abnormal bipolar EVM, unipolar EVM recorded significantly more 
extensive RV electroanatomic scar involvement with a median RV low-voltage area of 68.5 cm2 (22.9–
98.7) and median percent RV area of 64.8% (39.8–95.3) compared with low voltages obtained by bipolar 
EVM (P<0.009; Figure 18). In all 16 patients (23%) with normal bipolar EVM, the use of unipolar EVM 
technique unmasked ≥1 regions of low voltage unipolar electrogram abnormality 37.3 cm2 (12.1– 
48.9); 26.2% (11.6–38.2; Figure 18). 
 
Figure 18. Representative bipolar and unipolar right ventricular (RV) endocardial voltage mapping 
(EVM) from 2 arrhythmogenic right ventricular cardiomyopathy (ARVC) patients. Patient #16: Right 
anterior oblique view of RV bipolar EVM showing preserved bipolar voltages values (A); right anterior 
oblique view of RV unipolar EVM from the same patient unmasking the presence of a significant 
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electroanatomic scar (B). Patient #47: Compared with right anterior oblique view of bipolar RV EVM 
(C), unipolar RV EVM (D) reveals a greater burden of low voltage electrogram area involving the RV 
outflow tract, infero-basal, and apex regions. 
 
 
 
 
Figure 19. Anatomic representation of regional distribution of bipolar low-voltage areas in the RV free-
wall. The septum was excluded from the analysis. RVOT = right ventricular outflow tract. 
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Figure 20. Surface ECG (top) and bipolar intracardiac electrocardiograms (bottom) sampled from within 
normal (A) and low-amplitude (B) right ventricular (RV) area in the same arrhythmogenic right 
ventricular cardiomyopathy/dysplasia (ARVC) patient. Normal voltage electrogram is characterized 
by a sharp, biphasic deflection with large amplitude and short duration (A). By comparison, electrogram 
recorded from low-voltage areas (i.e., electroanatomic scar) are fragmented with late activation and 
prolonged duration beyond the QRS complex. 
 
Follow-Up 
During a median follow-up of 41 (28–56) months, 19 patients (27.5%) reached the composite arrhythmic 
end point, with a 6.7% annual rate of major arrhythmic events. Eleven patients (16%) had an episode of 
sustained VT, 7 (10%) experienced ≥1 appropriate ICD interventions, either against VF (n=4) or 
VT (n=3), and 1 (1.4%) died suddenly. Among the 4 patients who experienced VF, 1 underwent 
orthotopic heart transplantation because of intractable recurrent VF storms. Table 4 shows the clinical 
characteristics of patients with or without major arrhythmic events during follow-up. Patients who 
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experienced arrhythmic events significantly more often had a history of cardiac arrest or syncope (73% 
vs. 16%; P=0.001), and abnormal bipolar EVM (100% vs. 68%; P=0.003). 
Figure 21 shows Kaplan–Meier analysis of survival from the index combined end point of sustained VT, 
appropriate ICD intervention, and SCD for the overall population, stratified by bipolar EVM findings. 
Overall, the annual event rate was 11.4%/y in patients with an abnormal bipolar EVM and 0%/y with a 
normal bipolar EVM (logrank: P=0.02). 
 
 
Figure 21. Kaplan–Meier analysis of freedom from adverse events stratified by the presence of abnormal 
bipolar endocardial voltage mapping (EVM). 
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Table 4. Characteristics of patients with and without arrhythmic events during follow-up. 
 Events 
N=19 (28%) 
No events 
N=50 (72%) 
 
P 
Age (yrs), (mean ± SD) 34.7±13.1 38.3±13.6 0.33 
Sex (male), n (%) 14 (74) 36 (72) 0.95 
Family history of sudden death (<35 years), n (%) 6 (32) 10 (20%) 0.39 
History of cardiac arrest or syncope, n (%) 14 (73) 8 (16) 0.001 
Non-sustained VT, n (%) 10 (53) 34 (68) 0.42 
Sustained VT, n (%) 6 (32) 6 (12) 0.06 
RVEVD (ml/m2, mean ±S D) 85.3±28.6 84.4±32.0 0.91 
RVFAC (%, mean ± SD) 37.3±5.9 37.2±6.6 0.82 
LVEVD (ml/m2, mean ± SD) 62.0±12.4 68.9±17.8 0.11 
LVEF (%, mean ± SD) 50.4±7.9 50.2±9.0 0.93 
Fragmented bipolar electrograms 15 (79) 32 (64) 0.37 
Inducibility at PVS, n (%) 
VT, n (%) 
VF, n (%) 
Antiarrhythmic drug therapy, n (%) 
11 (58) 
9 (47) 
2 (11) 
15 (79) 
23 (46) 
19 (38) 
4 (8) 
42 (84) 
0.46 
0.67 
1.00 
0.96 
Abnormal bipolar-EVM, n (%) 19 (100) 34 (68) 0.003 
Abnormal unipolar-EVM, n (%) 19 (100) 50 (100) 1.00 
Abbreviations as in Table 3. 
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Electrophysiological Study 
Overall, the annual event rate was 6.1%/y in patients who were inducible at PVS and 7.1%/y in those who 
were non-inducible (logrank: P=0.46; Figure 22). Of 34 patients who were inducible at PVS, 23 (68%) 
did not experience major arrhythmic events during the follow-up (i.e., false positives), whereas 8 of 35 
(23%) non-inducible patients had malignant events (i.e., false negatives). The type of ventricular 
tachyarrhythmia which was inducible at the time of PVS (either VT or VF) did not predict either the 
presence of bipolar electroanatomic scar or the occurrence of arrhythmic events during follow-up. 
Patients with and without events during follow-up had a similar prevalence of RV fragmented bipolar 
electrograms (79% vs 64%). 
 
 
 
Figure 22. Kaplan–Meier analysis of freedom from adverse events stratified by inducibility of ventricular 
arrhythmias by programmed ventricular stimulation (PVS) ; (PVS +: inducible); (PVS-: non inducible). 
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Predictors of Events 
Predictors of adverse events during follow-up are listed in Table 5.  
 
Table 5. Predictors of arrhythmic events during follow-up 
 Univariate analysis Multivariable analysis 
 HR CI P HR CI P 
Age 1.0 1.0-1.0 0.7    
Sex (male) 1.1 0.4-3.3 0.8    
Family history of sudden death 1.1 0.4-3.0 0.9    
History of cardiac arrest or syncope 3.4 1.4-8.8 0.03 2.4 0.8-6,2 0.11 
Non-sustained VT 1.8 0.3-5.7 0.7    
Sustained VT 1.1 0.4-2.5 0.9    
RVEVD (ml/m2) 1.1 0.9-1.3 0.8    
RVFAC (%) 1.0 0.9-1.1 0.5    
LVEVD (ml/m2) 0.9 0.9-1.0 1    
LVEF (%) 1.0 0.9-1.1 0.9    
Fragmented bipolar electrograms 1.2 0.7-3.1 0.32    
Inducibility at PVS 1.4 0.5-5.0 0.4    
Antiarrhythmic drug therapy 0.9 0.3-3.4 0.8    
Abnormal bipolar-EVM† 1.7 1.5-2.0 <0.001 1.6 1.2-1.9 <0.001 
Abnormal unipolar-EVM† 1.3 0.6-4.3 0.3    
† HR for 5% interval   Abbreviations as in Table 3.  
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Univariate predictors of events were a previous history of cardiac arrest or syncope and extent of 
abnormal bipolar EVM. The overall arrhythmic risk increased with percentage of abnormal bipolar EVM 
(HR, 1.7 per 5% abnormal EVM increase; 95% CI, 1.5–2.0; P<0.001; Figure 23). At multivariable 
analysis the amount of abnormal bipolar EVM was an independent predictor of events (HR, 1.6 per 5% 
increase of abnormal EVM percentage; 95% CI, 1.2–1.9; P<0.001). The amount of abnormal bipolar 
EVM was a predictor of events (HR, 1.4 per 5% increase of abnormal bipolar EVM percentage; 95% CI, 
1.1– 1.9; P=0.004) even in the subgroup of 55 patients without previous sustained VT or previous cardiac 
arrest. According to c-statistic, the best cut-off value for abnormal bipolar EVM % area was 27.8% 
(c=0.74). 
 
 
Figure 23. Predicted probability of reaching the combined arrhythmic end point at 1, 2, and 3 years on 
the basis of the extent of abnormal bipolar endocardial voltage mapping (EVM). 
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Subanalysis of the EAS positive group 
 
Clinical Characteristics 
Data from forty nine out of the 53 patients [38 males, median age 35 (28-46) years] who showed an 
abnormal EVM with evidence of ≥1 RV-EAS were used for further correlation of non invasive features 
with the extent of EAS (figure 24). The remaining four patients were excluded from the subanalysis for 
the poor quality of their non-invasive data. The baseline clinical characteristics and instrumental findings 
of the study sample are summarized in Table 6. Twenty four patients (49%) had a family history of 
premature (˂35 years) sudden death (n=14, 29%) or ARVC (n=10, 20%). Thirty three patients had a 
history of palpitations (67%); 13 (27%) of syncope and 5 (10%) of cardiac arrests. Eleven patients (22%) 
experienced a previous sustained ventricular tachycardia (VT).  
 
 
 
Figure 24. A breakdown of the study population.  
ARVC: Arrhythmogenic right ventricular cardiomyopathies; RV-EAS: right ventricular electroanatomical 
scar.  
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Table 6 – Baseline clinical characteristics of the sub-analysis sample. 
Males 38 (77) 
Age (years) 35 (28-46) 
Family history 
Sudden death 
ARVC 
 
14 (29) 
10 (20) 
Personal history 
Palpitations 
Syncope 
Sustained VT episodes 
Cardiac arrest 
 
33 (67) 
13 (27) 
11 (22) 
5 (10) 
24-Hour ECG-Holter 
Frequent (500/day) PVBs 
Non-sustained VT (> 2 PVBs) 
 
42 (86) 
30 (61) 
ECG abnormalities 
Left axis deviation 
Right axis deviation 
S wave > 60 msec in V1-V3 
Low QRS voltages 
QRS duration > 110 mses 
Epsilon Waves 
Negative T-waves* 
 
8 (16) 
6 (12) 
19 (39) 
14 (29) 
21 (43) 
10 (20) 
32/46 (70) 
Late potentials on SAECG 30 (61) 
Echocardiographic findings 
RV end-diastolic volume (ml/m
2
) 
RV fractional area change (%) 
LV end-diastolic volume (ml/m
2
) 
LV ejection fraction (%) 
 
80 (63-96) 
30 (28-40) 
59 (56-61) 
62 (55-73) 
 
Results are shown as n (%) or as median (25-75iles). * 3 patients 
with complete right bundle branch block were excluded. 
EBM=endomyocardial biopsy; PVBs=premature ventricular beats; 
LV=left ventricle; RV=right ventricle; SAECG=signal averaged 
ECG; VT=ventricular tachycardia. 
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At 24-hour ECG-Holter monitoring, frequent (> 500/day) premature ventricular beats were documented 
in 42 (86%) patients and non-sustained VT (> 3 ventricular ectopic beats) in 30 patients (61%). Thirty 
four patients had undergone endomyocardial biopsy with fibrofatty replacement documented in 24 (71%). 
 
12-lead ECG and SAECG 
Twelve-lead ECG was completely normal in 5 (10%) individuals. The other 44 (90%) patients showed the 
following ECG abnormalities: left axis deviation (n=8, 16%); right axis deviation (n=6, 12%); complete 
right bundle branch block (n=3, 6%); S wave >60 msec (n=19, 39%); low QRS voltages (n= 14, 29%); 
QRS duration >110 msec (n=21, 43%) and epsilon waves (n=10, 20%). Negative T waves were recorded 
in 32/46 (70%) patients and showed the following distribution: 1) right precordial leads (V1-V3) in 8 
(17%) patients, 2) right precordial leads extending to lateral precordial leads (V4-V6) in 11 (24%),and 3) 
both precordial (V2-V6) and inferior leads in 13 (28%). The presence of late potentials on SAECG was 
documented in 30 (61%) patients. 
Twelve-lead ECG was completely normal in 5 (10%) individuals. The other 44 (90%) patients showed 
ECG abnormalities as demonstrated in table 6. Negative T waves were recorded in 32/46 (70%) patients 
and showed the following distribution: 1) right precordial leads (V1-V3) in 8 (17%) patients, 2) right 
precordial leads extending to lateral precordial leads (V4-V6) in 11 (24%),and 3) both precordial (V2-V6) 
and inferior leads in 13 (28%). The presence of late potentials on SAECG was documented in 30 (61%) 
patients. 
 
Endocardial Voltage Mapping 
High-density EVM was successfully acquired during sinus rhythm in all patients, with a median number 
of sites sampled of 203 (182-210). All patients showed ≥1 dense EAS (bipolar signal amplitude of 
endocardial electrograms <0.5 mV), which appeared sharply demarcated and typically surrounded by a 
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border zone with reduced signal amplitudes (0.5 to 1.5 mV). The median extent of total RV-EAS 
(including both dense scar and border zone) was 33 cm2 (12.4-67.8) corresponding to a median 22.5% 
(5.5-31.7%) of the total RV area. The involved RV regions were the infero-basal in 48 (98%) patients, the 
antero-lateral in 27 (55%), the RV outflow tract in 23 (47%) and the apical in 15 (31%).  
 
Correlation of results  
Correlation between echocardiographic EVM and echocardiographic findings are shown in figure 25. 
There was a significant correlation between the degree of right ventricular dilation/dysfunction and the 
RV-EAS % area. Correlation between ECG abnormalities and the RV-EAS% area is shown in Table 7. 
All 5 (10%) patients with a normal ECG had an RV-EAS area <10%. At univariate analysis, the presence 
of epsilon waves and negative T-waves were associated with a statistically significant greater RV-EAS% 
area. There was a significant correlation between the extent of negative T-waves across the ECG 12 leads 
and the RV-EAS% area (p for trend <0.001) (Figure 26). Normal T-waves were associated with a median 
EAS% area of 4.9% (4.5-6.4), negative T-waves in V1-V3 of 22.0% (8.5-30.6), negative T-waves in V1-
V3 extending to lateral precordial leads (V4-V6) of 26.8% (11.5-35.2) and negative T-waves in both 
precordial (V2-V6) and inferior leads of 30.2% (24.8-33.0) (p for trend <0.001). The extent of negative T-
waves across 12 leads was also significantly associated with both RV-EDV (p=0.01) and RV-FAC 
(p=0.01) (Table 8). 
At multivariate analysis, after adjustment for the presence of epsilon waves, RV-EDV and RV-FAC, the 
extent of negative T-waves remained the only independent predictor of RV-EAS% area (B=4.4, 95% CI 
1.3-7.4, p=0.006) (Table 9). Representative cases encompassing the spectrum of ECG repolarization 
abnormalities and EVM findings are shown in figure 27. 
The analysis of correlation between ECG abnormalities and EAS involvement of specific RV regions 
showed a statistically significant association between 1) the presence of negative T-waves in the inferior 
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leads with the involvement of the RV infero-basal area (p=0.008) and 2) the presence of late potentials at 
SAECG with the involvement of the RV outflow tract (p=0.01). 
 
Table 7 – Differences of percentage right ventricular electroanatomic scar according to the presence or 
absence of major ECG abnormalities and late potentials. 
 RV-EAS area %  
ECG abnormalities Yes No P 
Left axis deviation 18.9 (10.3-33.8) 24.8 (5.4-31.7) 0.98 
Right axis deviation 20.4 (4.9-32.8) 23.8 (8.8-31.8) 0.87 
S wave > 60 msec 24.8 (5.6-31.6) 14.8 (7.9-31.9) 0.88 
Low QRS voltages 30.8 (8.1-33.9) 19.1 (5.1-31.4) 0.34 
dQRS > 110 mses 28.9 (11.0-33.0) 12.3 (5.1-31.4) 0.14 
Epsilon waves 30.0 (10.1-37.0) 15.6 (5.1-27.8) 0.04 
Negative T-waves* 29.6 (13.1-32.2) 4.9 (4.5-6.4) <0.001 
Late potentials on SAECG 29.6 (10.3-31.7) 10.6 (5.1-32.2) 0.30 
* 3 patients with complete right bundle branch block were excluded 
SAECG=signal averaged ECG 
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Table 8 – Correlation between extent of negative T-waves and right ventricular dilation/dysfunction. 
 
No 
NTW 
NTW 
in V1-V3 
NTW 
beyond V3 
NTW in 
precordial and 
inferior leads 
P 
RV-EDV (ml/m
2
) 65 (55-80) 75 (59-80) 84 (72-118) 97 (75-104) 0.01 
RV-FAC (%) 40 (35-42) 35 (33-40) 31 (30-35) 32 (27-39) 0.01 
 
FAC=fractional area change; EDV=end-diastolic volume; NTW=negative T-waves; RV=right ventricular 
 
 
Table 9 – Multivariate analysis for predictors of RV-EAS% area 
 B (95% C.I.) p 
Epsilon waves 2.9 (-5.4 - 11.2) 0.49 
Extent of NTW 4.4 (1.3 - 7.4) 0.006 
RV-EDV (ml/m
2
) 0.04 (-0.2 – 1.4) 0.63 
RV-FAC (%) -0.7 (-1.4 – 0.2) 0.09 
 
FAC=fractional area change; EDV=end-diastolic volume; NTW=negative T-
waves; RV=right ventricular 
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Figure 25: (A) Correlation between right ventricular fractional area change (RV FAC) and amount of RV 
EAS size (EAS% area). (B) Correlation between right ventricular end diastolic volume (RV EDV) and 
EAS% area. 
 
 
Figure 26. Correlation between extent of negative T-waves (NTW) and amount of right ventricular 
electroanatomical scar size 
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Follow-up 
During a median follow-up of 36 (20-51) months, 18 patients (37%) experienced major arrhythmic events 
including sudden death (n=1), sustained ventricular tachycardia (n=11) and appropriate ICD intervention 
on ventricular tachycardia/fibrillation (n=7). Figure 28 shows the Kaplan-Meier analysis of survival from 
major arrhythmic events stratified by the extent of negative T-waves. All 5 patients with a normal ECG 
had an uneventful outcome. 
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Figure 27. Representative cases of ARVC patients encompassing the spectrum of electrocardiographic 
(ECG) repolarization abnormalities and endocardial voltage mapping (EVM) findings. 
(A) twelve-lead ECG of patient #21showing no repolarization abnormalities. 
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(B) Right oblique anterior view of EVM showing segmental right ventricular electroanatomic scars (RV-
EAS) involving the inferobasal and outflow tract regions with replacement of the 8.4% of the RV. 
(C) twelve-lead ECG of patient #5 showing T-wave inversion in V1-V3. 
(D) Right oblique anterior view of EVM showing a total RV-EAS of 19.4% which involves the 
inferobasal, anterolateral and outflow tract regions. 
(E) twelve-lead ECG of patient #21showing T-wave inversion in V1-V6, L2, L3 and aVF and epsilon 
waves in V1, V2. 
(F) Anteroposterior view of EVM showing a total RV-EAS of 68.1% which myocardial substitution of 
the inferobasal, anterolateral, outflow tract and apical regions. 
 
 
 
Figure 28. Kaplan-Meier analysis of survival from major arrhythmic events according to the extent of 
negative T-waves. 
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Effects of exercise on right precordial negative T waves in arrhythmogenic 
right ventricular cardiomyopathy 
   
Methods 
 
Study population  
 The study sample included 35 consecutive ARVC patients undergoing exercise testing at the time 
of first clinical evaluation during the period 2010-2012. All patients underwent comprehensive clinical 
evaluation including family and personal history, ECG, signal-averaged ECG (SAECG), 24-hour ECG 
Holter monitoring, exercise testing, echocardiogram and cardiac magnetic resonance. Technical 
equipment, protocols, and reference values are similar to those reported in Cohort 1.  
Patients were enrolled in the study if 1) they fulfilled the criteria (2 major criteria, 1 major criteria plus 2 
minor criteria or 4 minor criteria) for definite diagnosis of ARVC according to the 2010 Revised Task 
Force criteria (11),
 
2) showed negative T-waves in right precordial leads (V1-V3) and 3) were not 
undergoing beta-blockers or anti-arrhythmic drugs at the time of exercise testing.  
 
Exercise test 
 All subjects underwent maximal bicycle exercise testing at the time of first clinical evaluation 
according to a protocol of 25-50 watt increments every 3 minutes. Twelve-lead ECG, heart rate and blood 
pressure were recorded at baseline, during the third minute of each exercise stage, at peak exercise and 
every 3 minutes into recovery. Criteria for interrupting the test were target heart rate (220 minus age), 
complex ventricular arrhythmias, hypotension, symptoms or exhaustion. The ECG patterns of right 
precordial negative T-waves in response to exercise were classified as persistence of T-wave inversion i.e. 
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no or minor (<50%) changes of negative T-waves amplitude; T-wave normalization i.e. negative T-wave 
becoming upright with exercise; and partial reversal when there was a positive increased in the T-wave 
amplitude ≥50% in ≥2 contiguous leads. 
  
Control group 
 A group of 41 healthy subjects, with age and gender comparable to the ARVC study patients 
served as controls. They exhibited right precordial negative T-waves with no ST-segment elevation on 
ECG obtained at pre-participation screening and underwent the same comprehensive cardiovascular study 
protocol including exercise testing. 
 
Statistical analysis  
 Categorical differences between groups were evaluated by the χ2 test or the Fisher exact test as 
appropriate. Continuous variables were expressed as mean ± standard deviation and compared with 
Student’s T-Test or with the Rank sum test as appropriate. Normal distribution of continuous variables 
was assessed by the Kolmogorov-Smirnov test. A value of P<0.05
 
was considered significant. Statistics 
were analyzed with SPSS
 
version 17 (SPSS Inc, Chicago, Ill). 
 
Results 
 
Clinical characteristics 
ARVC patients 
The study population included 35 ARVC patients (19 males, mean age 22.2±6.2 years). Four patients 
(11%) had a positive family history for sudden cardiac death and 9 (26%) for ARVC. At the time of first 
clinical evaluation, 19 (54%) patients were symptomatic for palpitations, 4 (11%) for chest pain and 8 
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(23%) for syncope. Seven (20%) individuals experienced a previous sustained ventricular tachycardia 
(VT) and 1 (3%) suffered cardiac arrest due to ventricular fibrillation. At baseline ECG, 8 (23%) 
exhibited epsilon waves, 11 (31%) low voltages in limb leads and 15 (43%) a S wave >50 msec in V1. 
Negative T-waves extended beyond V3 in 17 (49%) patients. Late potentials on SAECG were 
demonstrated in 21 (60%) patients. On 24-hour Holter monitoring, frequent (≥500/24 hours) premature 
ventricular beats in 27 (77%) patients and non-sustained VT in 22 (63%). Morpho-functional right 
ventricular (RV) abnormalities, either global or regional, were documented at echocardiography in all 
patients; left ventricular (LV) dilatation/dysfunction was identified in 7 patients (20%).  
Mean RV end-diastolic area was 28.0±6.0 cm
2
, mean RV fraction area change was 35.4±8.6%, mean LV 
end-diastolic volume was 61.8±10.1 ml/m
2
 and mean LV ejection fraction was 57.4±7.2%.  
Control group 
All 41 athletes (26 males, mean age 19.5±9.2 years) were asymptomatic, had a negative family history 
and showed no evidence of structural heart disease, late potentials or ventricular arrhythmias.  
 
Exercise testing 
ARVC patients 
At peak of exercise, the patients reached a mean power of 162±43 watts, a mean heart rate of 168.8±23.9 
beats per minute (bpm) (83.6±12.6% of target heart rate) and a double product (systolic blood pressure x 
heart rate) of 27643±6361 bpm x mmHg. Reasons for interruption were target heart rate in 20 (57%) 
patients and physical exhaustion in 15 (43%). On resting electrocardiogram, deepest negative T-wave in 
the right precordial leads had a mean amplitude of 0.41±0.14 mV and was observed more often in lead V2 
(27/35, 77%). Right precordial negative T-waves persisted with exercise in 3 (9%) patients, normalized in 
12 (34%) and partially reverted in 20 (57%). T-waves became positive or less negative at a mean power 
of 110±14 watt and gradually returned to baseline during the post-exercise phase. Representative cases of 
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response to exercise of right precordial repolarization abnormalities and ventricular arrhythmias are 
shown in Figure 29. One patient showed significant ST-segment depression at peak of exercise: he 
underwent myocardial perfusion scintigraphy that excluded an underlying myocardial ischemia. 
Ventricular arrhythmias were induced or increased by exercise in 10 (29%) ARVC patients and reduced 
or suppressed in 15 (42%); in the remaining 10 subjects (29%) no arrhythmias were observed thorough 
the exercise test.  
Control group 
At peak of exercise, the controls reached a mean power of 158±24 watts, a mean heart rate of 177.0±15.1 
bpm (88.3%±7.2% of target heart rate) and a double product (systolic blood pressure x cardiac frequency) 
of 28314±4207 bpm x mmHg. Reasons for interruption were target heart rate in 26 (63%) and physical 
exhaustion in 15 (37%). No patients showed significant ST-segment depression at peak of exercise or 
ventricular arrhythmias at baseline or during exercise. Persistence of right precordial negative T-waves 
with exercise was observed in 5 (12%) controls, T-waves normalization in 23 (56%) and partial reversal 
in 13 (32%). 
 
Correlation of results 
ARVC patients 
Correlation between changes of T-wave polarity and either clinical characteristics or exercise testing 
findings in ARVC patients are shown in Table 10 and 11. Patients with exercise-induced T-wave 
normalization were significantly younger (20.0±10.3 versus 28.7±8.4 years, p=0.03). There were no 
differences of exercise-induced right precordial T-wave pattern with regard to gender, personal and 
family history, echocardiographic and other ECG findings. Changes of negative T-waves at peak of 
exercise were independent from maximal power, heart rate, double product or reasons for test 
interruption. 
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Control group 
There was no correlation between right precordial T-wave patterns and age, gender and exercise testing 
findings. 
 
ARVC patients versus controls 
There were no significant differences between controls and ARVC patients with regard to age, sex, 
maximal power, heart rate and double product at peak of exercise. The overall prevalence of right 
precordial T-waves changes with exercise (normalization plus partial reversal) was similar in ARVC 
patients and controls (92% versus 88%, p=1.00) while when we compared only complete normalization, 
there was a statistically non significant trend towards a higher prevalence in controls (59% versus 34%, 
p=0.06). 
 
Table 10 – Comparison of clinical characteristics of ARVC patients (n=35) with and those without 
complete normalization of right precordial negative T waves at peak of exercise. 
 Patients with 
normalization 
N=12 
Patients without 
normalization 
N=23 
P 
Sex (male) 6 (50) 13 (57) 0.71 
Age 20.0+10.3 28.7+8.4 0.03 
Family history 
SD 
ARVC 
 
1 (8) 
5 (42) 
 
3 (13) 
4 (17) 
 
1.0 
0.22 
 
Personal history 
Palpitations 
 
 
6 (50) 
 
 
13 (57) 
 
 
0.74 
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Chest pain 
Syncope 
Sustained VT 
Cardiac arrest 
1 (8) 
1 (8) 
3 (25) 
1 (8) 
3 (13) 
7 (30) 
4 (17) 
0 
1.0 
0.22 
0.67 
0.34 
ECG findings 
Epsilon waves 
Low QRS voltage in limb leads 
S wave >50 msec 
Negative T-wave beyond V3 
 
2 (17) 
2 (17) 
3 (25) 
2 (17) 
 
8 (35) 
9 (39) 
12 (52) 
2 (9) 
 
0.43 
0.26 
0.17 
0.64 
Maximal negative T-wave amplitude (mV) 0.39±014 0.42±0.13 0.73 
Late potentials on SAECG 5 (42) 16 (70) 0.11 
24-hour Holter monitoring 
≥500 PVB/24-hour 
Non sustained VT 
 
10 (83) 
9 (75) 
 
17 (74) 
13 (57) 
 
0.69 
0.29 
Echocardiographic findings 
RV end-diastolic area (cm
2
) 
RV fractional area change (%) 
RV region WMA 
LV end-diastolic volume (ml/mq) 
LV ejection fraction (%) 
LV region WMA 
 
27.6+5.7 
33.4±6.7 
10 (83) 
59.2+8.9 
58.0+4.5 
4 (33) 
 
28.2+7.2 
36.5±9.3 
21 (91) 
63.0+10.6 
57.1+8.3 
3 (13) 
 
0.80 
0.33 
0.59 
0.31 
0.75 
0.20 
 
PVB=premature ventricular beats, LV=left ventricle; RV=right ventricle; SAECG=signal-averaged 
electrocardiogram; SD=sudden death; VT=ventricular tachycardia, WMA=wall motion abnormalities. 
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Table 11 – Comparison of results of exercise testing in patients with and those without complete 
normalization of right precordial negative T-waves at peak of exercise. Bpm=beats per minute, HR=heart 
rate, SBP=systolic blood pressure 
 Patients with 
normalization 
N=12 
Patients without 
normalization 
N=23 
P 
Peak of exercise 
Power (Watt) 
HR (bpm) 
HR*SBP (bpm*mmHg) 
% target HR 
 
177+42 
164.3+25.8 
29722+4430 
85.0+11.1 
 
155+43 
156.1+23.1 
26782+6909 
82.1+13.4 
 
0.25 
0.36 
0.29 
0.87 
Reasons for interruption 
Target frequency 
Exhaustion 
Symptoms 
Hypotension 
 
8 (67) 
4 (33) 
0 
0 
 
12 (52) 
9 (48) 
0 
0 
 
0.72 
ST-segment depression 0 1 (4) 1.0 
Ventricular arrhythmias 
Absent 
Induced/increased complexity 
Decreased complexity/suppressed 
 
2 (17) 
6 (50) 
4 (33) 
 
8 (35) 
9 (39) 
6 (26) 
 
0.53 
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Figure 29.Representative cases of right precordial negative T-waves changes during exercise testing. 
 
A) Patient #7: a 20 year-old female with negative T-wave in V1-V3 on baseline ECG both complete 
normalization of the T waves and suppression of ventricular arrhythmias occur at peak of exercise (125 
watts, double product 23.960 bpm x mmHg) B) Patient #14: an 18 year-old male with negative T-wave in 
V1-V3 on baseline ECG and partial reversal of negative T-waves at peak of exercise (175 watts, double 
product 28.350 bpm x mmHg). C) Patient #20: a 25 year-old male with negative T-wave in V1-V3/V4 on 
baseline ECG and complete normalization of right precordial T-waves at peak of exercise (175 watts, 
double product of 30.200 bpm x mmHg). D) Patient#22: a 31 year-old male with negative T-wave in V1-
V4 on baseline ECG and persistence of negative T-waves at peak of exercise (150 watts, double product 
of 26.840 bpm x mmHg 
.
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DISCUSSION 
 
 The electrocardiogram is a crucial diagnostic and prognostic test, as it is readily available tool and 
can be extensively used in countries, like Egypt, where an ARVC program is still in its evolving phase 
(figure 30). In this work, we further studied some of the electrocardiographic features of ARVC. First, we 
proved that in comparison to other non-invasive tools, negative T waves present in the right and inferior 
leads correlate best with the presence and extent of RV EAS detected by endocardial voltage mapping in 
ARVC. Second, we demonstrated that these negative T waves are surrogate to RV EAS size as a 
prognosticator for arrhythmic risk in patients with ARVC. Finally, we specifically studied whether right 
precordial negative T waves of ARVC persist (or normalize) during exercise testing and whether that 
response to exercise may be a helpful diagnostic feature. Our results showed that there is no statistical 
difference in the rates of normalization of right precordial negative T waves observed with ARVC and 
those observed in controls.  
 
Electrovoltage mapping as a diagnostic and a prognostic tool in ARVC 
 Endocardial voltage mapping is an emerging tool that has the ability to accurately identify and 
quantify RV regions with low-amplitude electric signals (i.e. EAS areas), which correspond to areas of 
fibrofatty myocardial replacement leading to loss of local electrical activity(5)(6)(7)(8)(9).  
We evaluated the prognostic value of EVM in ARVC patients and showed that the presence and extent of 
abnormal RV bipolar-EVM was a powerful and independent predictor of arrhythmic risk. Moreover, 
EVM appeared to be superior to traditional arrhythmic risk factors, including RV dilation/dysfunction and 
inducibility of sustained ventricular tachycardia at programmed ventricular stimulation. Nevertheless, the 
routine use of EVM in ARVC patients for RV scar quantification and risk stratification is potentially 
limited because of its invasive nature, limited availability and high cost. Hence, it was crucial to evaluate 
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whether 12-lead ECG and SAECG allow non-invasive estimation of RV electrical lesions in ARVC 
patients. 
 
ECG abnormalities in ARVC 
 Twelve-lead ECG is a fundamental part of the evaluation of ARVC patients. Inverted T-waves in 
right precordial leads, delayed S-wave upstroke, epsilon waves, low QRS voltages in limb leads and intra-
ventricular conduction defects are the most striking ECG abnormalities in ARVC patients with an overt 
disease phenotype(10)(11)(12)(13). Accordingly, the present study showed that surface 12-lead ECG was 
abnormal in 90% of ARVC patients who had a diagnosis of definitive ARVC according to the 2010 
International Task Force criteria and showed an abnormal EVM with evidence of ≥1 low amplitude areas. 
On the other hand, we found that patients with a normal ECG showed limited EAS involvement, a finding 
suggesting that the absence of ECG abnormalities reflects early/minor electrical disease of RV 
myocardium. Our findings are in agreement with those of Santangeli et al. who showed that an abnormal 
EVM was always associated with an abnormal ECG, although in their study a quantitative EAS area 
measurement and, thus, a correlation between ECG abnormalities and percentage of RV-EAS was not 
performed (120). 
 
Negative T waves as surrogate for RV electroanatomic scar size 
 Previous studies demonstrated that T waves in ARVC typically become negative with the disease 
worsening and that greater extent of negative T waves across the ECG 12 leads is associated with more 
severe RV dilation and dysfunction(12)(13)(14). Our study results extend these previous observations by 
showing that negative T-waves allow to estimate the amount of EAS and contribute to predict the 
arrhythmic outcome of ARVC patients. The presence of ECG negative T waves was associated with a 6-
times greater RV-EAS% area and the extent of negative T waves across ECG 12-leads was an 
independent predictor of RV-EAS size, regardless of the severity of RV dilation/dysfunction. The link 
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between repolarization abnormalities and the underlying EAS substrate was further substantiated by 
Kaplan-Meier analysis showing a statistically significant association between the extent of negative T 
waves and the occurrence of major arrhythmic events during follow-up. Over a long term follow-up, 53% 
of patients with negative T waves experienced sudden death, sustained ventricular tachycardia, or 
appropriate ICD interventions versus 7% of those without repolarization abnormalities.  
 
The electrogenesis of negative T waves in ARVC 
 The electrogenesis of T waves inversion in ARVC and its relation with RV-EAS lesions remains 
to be elucidated. Based on our findings, one can speculate that replacement of RV myocardium by fibro-
fatty tissue induces a ventricular electrical remodeling with changes of transmural and/or regional 
activation and repolarization times. These electrophysiological changes may become critical enough to 
cause reversal of repolarization gradients and lead to T-waves inversion on the ECG, with a “dose-effect” 
relationship between ECG repolarization abnormalities and electrical scar lesions. 
Causes of negative T waves in the population 
Causes of negative s on 12-lead ECG range from entirely benign conditions such as the persistent juvenile 
T-wave pattern to life-threatening disorders including coronary artery disease and cardiomyopathies.11 T-
wave inversion is a normal feature of 12-lead ECG in pediatric age. During the first decade of life, 
changes of electrical predominance from the right ventricle (RV) to the left ventricle result in a gradual 
reversal of T-wave polarity, which progresses from left to right precordial leads as children grow older 
and leads after the puberty to the adult ECG pattern, characterized by negative T wave limited to V1. 
Persistence of T wave inversion in leads V1 to V2/V3 (known as persistence of the juvenile pattern of 
repolarization) may be observed in about 3% of healthy adults(15)(16)(19). In contrast, as earlier 
mentioned T wave inversion in right precordial leads is the most common ECG abnormality of ARVC, 
which is a recognized important cause of sudden cardiac death in young people and athletes (11)(12). 
Because clinical manifestations of ARVC usually occur after the puberty, the persistence of right 
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precordial T wave inversion (beyond V1) in the postpubertal age raises the problem of the differential 
diagnosis between a benign juvenile pattern of repolarization and a developing heart muscle disease. 
 
Clinical work-up for negative T waves in sports screening 
 The clinical workup for differential diagnosis between pathologic and nonpathologic negative T 
waves traditionally includes electrocardiographic exercise testing. The current perspective is that negative 
T waves usually revert to normal with exercise in healthy subjects whereas they persist in patients with 
structural heart muscle disease(15). Changes of NTWs with exercise are considered a favorable feature 
supporting the benign nature of repolarization abnormalities(15)(121). However, the available data in 
favor of this concept are very limited. Serra-Grima et al studied 22 healthy athletes with NTWs at 
baseline ECG and observed in all cases a tendency to normalization during exercise. Pelliccia et al studied 
the clinical outcome of 81 elite athletes who exhibited marked repolarization abnormalities and a normal 
baseline echocardiogram. Five of 81 (6%) athletes developed many years later structural abnormalities 
consistent with a cardiomyopathy on serial echocardiographic exams. Exercise-induced partial or 
complete normalization of negative T waves with exercise had been observed in 58 of 76 (77%), whereas 
all athletes with a delayed occurrence of cardiomyopathy did not show any modifications of 
repolarization abnormalities during exercise testing(121)(122). 
 
Value of exercise testing for negative T waves 
 A systematic study evaluating the changes of negative T waves with exercise has not been 
previously performed in patients with ARVC. Our study was designed to specifically assess whether right 
precordial negative T waves of ARVC persist (or normalize) during exercise testing and whether response 
to exercise may be a helpful diagnostic feature. We observed a complete normalization of right precordial 
NTWs with exercise in 34% of patients with ARVC and a trend toward normalization (i.e., either 
normalization or partial reversal) in 91%, figures similar to those observed in controls. Moreover, there 
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were no statistically significant differences between patients with ARVC with those without complete 
normalization of NTWs at peak of exercise with regard to disease phenotype such as symptoms, RV 
morphofunctional abnormalities, or ventricular arrhythmias. 
 
Electrophysiological basis for exercise induced negative T wave changes 
 The electrophysiological mechanism underlying normalization of NTWs in ARVC remains to be 
elucidated. We may speculate that adrenergic stimulation may induce transient changes in transmural or 
regional activation times and also in the action potentials durations into the diseased RV 
myocardium. These changes, in a subgroup of patients with ARVC, can be critical enough to cause 
reversal of repolarization gradients leading to NTWs at baseline. 
 
Clinical implications 
 The observation that right precordial NTWs normalize or tend to revert with exercise in most 
patients with ARVC has important clinical implications. It suggests that exercise induced changes of right 
precordial negative T waves do not add to the accuracy of clinical workup for differentiating between 
benign and cardiomyopathic repolarization abnormalities. Our results raise doubts about the current 
interpretation of NTWs normalization as a favorable exercise testing response, which may contribute to 
exclude an underlying cardiovascular disease with its inherent arrhythmic risk. Because in our study 
exercise-induced changes of NTWs were unrelated to ARVC phenotypic manifestations such as 
symptoms, RV morphofunctional abnormalities, or ventricular arrhythmias, they also appear of limited 
value for clinical and prognostic assessment of patients with ARVC. 
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Study limitations 
 Although both study cohorts were relatively large for ARVC, still a small number of patients and 
outcomes were analyzed, linked predominantly to relatively low disease prevalence, low 
event rate, and the low prevalence of negative T waves in general population. The small number of events 
limits both the power to detect associations and the ability to control completely for all potential 
confounders in the multivariable models. Nonetheless, we believe that our study results and statistical 
analysis indicate important trends that are of clinical relevance for the management of ARVC patients. 
Also, the different rate of ICD implantation (54% of patients with an abnormal bipolar EVM versus 12% 
of those with normal bipolar EVM) may represent a study bias with regard to arrhythmia detection. 
However, ICD were routinely programmed to include a monitoring zone that identified VT with a rate 
>160 bpm; this lessens the potential limitation of not homogeneous distribution of ICD, because slower, 
asymptomatic VTs remained equally undetected in both patient subgroups, regardless of ICD monitoring. 
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Figure 30. ECG of a 36 female Egyptian patient with ARVC. Note the negative T waves in V1-V5, the 
prolongation of activation from the nadir of S to the end of QRS complex, and the low voltage of QRS in 
limb leads. 
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